Evaluation of Serum Ferritin as a Prognostic Marker in Acute Hemorrhagic Stroke by Sowri Rajan @ Govindaraj, R
EVALUATION OF SERUM FERRITIN AS A 
PROGNOSTIC MARKER IN ACUTE  
HEMORRHAGIC STROKE.   
 
Dissertation submitted in partial fulfillment of requirements for 
 
M.D. DEGREE IN GENERAL MEDICINE 
 
BRANCH I 
 
of 
 
THE TAMILNADU Dr. M.G.R. MEDICAL UNIVERSITY, 
CHENNAI, INDIA. 
 
 
 
MADRAS MEDICAL COLLEGE, 
 
CHENNAI 600003 
APRIL 2013 
  
CERTIFICATE 
 
This is to certify that the dissertation entitled   ―EVALUATION 
OF  SERUM  FERRITIN  AS  A  PROGNOSTIC  MARKER  IN  ACUTE 
HEMORRHAGIC STROKE ” is a    bonafide    work     done    
Dr.R.SOWRI RAJAN @ GOVINDARAJ, at Madras Medical College, 
Chennai in partial fulfillment of the university rules and regulations for award 
of M.D., Degree in General Medicine (Branch-I) under my guidance and 
supervision during the academic year 2010 -2013. 
 
 
 
 
 
 
Prof.E.DHANDAPANI M.D., 
Professor, 
Guide & Research Supervisor, 
Institute of Internal Medicine, 
Madras Medical College & 
Rajiv Gandhi Govt. General Hospital, 
Chennai – 3. 
 
 
 
 
 
 
Prof.V.KANAGASABAI M.D., 
The Dean 
Madras Medical College & 
Rajiv Gandhi Govt. General Hospital, 
Chennai – 3. 
 
Prof.N.RAGHU  M.D., 
       Director and Professor,  
       Institute of Internal Medicine, 
       Madras Medical College & 
       Rajiv Gandhi Govt. General Hospital, 
Chennai – 3. 
 
  
DECLARATION 
 
I solemnly declare that this dissertation entitled ―EVALUATION OF SERUM 
FERRITIN AS A PROGNOSTIC MARKER IN ACUTE  
HEMORRHAGIC STROKE” was done by me at Madras Medical College 
and Rajiv Gandhi Government General Hospital, during 2010-2013 under the 
guidance and supervision of Prof.E.DHANDAPANI, M.D. This dissertation is 
submitted to the Tamil Nadu Dr.M.G.R. Medical University towards the partial 
fulfillment of requirements for the award of M.D. Degree in General Medicine 
(Branch-I). 
Place: Chennai 
Date: 
 
 
Dr. R.SOWRI RAJAN@ GOVINDARAJ, 
MD GENERAL MEDICINE, 
Postgraduate Student, 
Institute of Internal Medicine, 
Madras Medical College, 
Chennai – 600003. 
 
  
ACKNOWLEDGEMENT 
 
At the outset, I thank Prof.V.KANAGASABAI M.D., Dean, Madras Medical 
College and Rajiv Gandhi Government General Hospital, Chennai-3 for having 
permitted me to use hospital resources for the study. 
 
I am grateful to Prof.N.RAGHU, M.D., Director and Professor, Institute of 
Internal Medicine, Madras Medical College and Rajiv Gandhi Government 
General Hospital, Chennai-3. 
 
I am indebted to Prof.E.DHANDAPANI, M.D., Professor of Medicine, 
Institute of Internal Medicine, Madras Medical College and Rajiv Gandhi 
Government General Hospital, Chennai-3 for his valuable guidance. 
 
I would like to thank Dr. K.THIRUMALVALAVAN M.D. and 
Dr.K.VIDHYA M.D., Assistant Professors,Madras Medical College and Rajiv 
Gandhi Government General Hospital, Chennai-3 for their scrutiny. 
 
I would also like to thank Prof. C.MARGARET H.O.D and all the professors 
and assistant professors of the Department of Hematology and the Department 
of Biochemistry for their continuous support and expert guidance. 
 
I express my sincere gratitude to all the patients who participated in the study. 
 
Lastly, I thank all my professional colleagues and Dr.Priya for their support and 
valuable criticism. 
  
TABLE OF CONTENTS 
 
S.No 
TITLE 
PAGE NO 
1. INTRODUCTION 1 
2. AIM OF THE STUDY 3 
3. REVIEW OF LITERATURE 4 
4. MATERIALS AND METHODS 61 
5. OBSERVATIONS AND RESULTS 66 
6. DISCUSSION 93 
7. CONCLUSION 97 
8. BIBLIOGRAPHY  
 ANNEXURE 
 ABBREVIATIONS 
 PROFORMA 
 MASTER CHART 
 BIBLIOGRAPHY 
 ETHICAL COMMITTEE APPROVAL 
ORDER 
 TURNITIN-PLAGIARISM SCREEN 
SHOT 
 
                            INTRODUCTION 
  Cerebrovascular disease is arguably most devastating of the neurological 
disease affecting mankind. The term stroke or apoplexy (Gr.being struck down) 
is applied to sudden focal neurological syndrome, specifically the type caused 
by cerebrovascular disease.  
 Intracerebral hemorrhage was first recorded by the Swiss physician 
Wepfer (1620–95) and in more detail by Morgagni (1682–1771) in Padua. 
Nonhaemorrhagic stroke, ‗serous apoplexy‘, greatly puzzled the medical 
community until cerebral softening (‗ramollissement’) was recognized as a 
pathological entity in 1820 by Rostan (1790–1866) in Paris. Initially it was 
regarded as an inflammatory condition. The term ‗infarction‘ was coined by 
Cohnheim, one of Virchow‘s disciples.A landmark in the recognition of the 
anatomical substrate of the stroke was the work of Morgagni (1682-1771)  
Professor of medicine and subsequently of pathological anatomy in Padua.  In 
1761 , Morgagni published a impressive series of clinicopathalogical 
observation collected over his lifetime at the age of 72. Morgagni not only 
confirmed the notion of crossed paralysis , but also firmly divided apoplexy into 
sanguineous apoplexy and serous apoplexy (1). Portal  (1742-1832) rightly 
emphasized that it was impossible to distinguish between the two during life 
(2). 
 The cerebrovascular disease include the following principle 
categories,1.Infarction –through occlusion of major arteries , small arteries or 
venous sinuses,2.Hemorrhage – most often through rupture of small arteries, 
arterioles, aneurysms or capillaries. 
 Strokes are common with annual incidence of 42-100/10000. It is the 
second most common cause of death in Europe and heart failure. It is the third 
most common cause of death after heart failure and cancer in united states. 
Overall it is the second most common cause of death  worldwide (3).  
Stroke Morbidity and Mortality in India 
 Prevalence 55.6 per 100,000 all ages (4);0.63 Million deaths (5) ;1.44-
1.64;million cases of new acute strokes every year (6.);6,398,000 DALYs 
(7.).12% of strokes occur in the population aged <40 years (8).28-30 day case 
fatality ranges from 18-41% (9, 10,11) 
 The consequence of stroke is devastating. Apart from the functions 
specific to the lost brain tissue, other essential mental faculties such as humor, 
mood, initiative, and speed of thought are severely affected. Sadly these 
attributes are ignored in the treatment of stroke patients. 
    AIMS OF THE STUDY. 
1. To find the serum ferritin levels in patients with                                                               
intracerebral hemorrhage.  
2. To find the serum ferritin level between different prognostic  
groups. 
 3.To assess the correlation between serum ferritin level and  severity 
of acute intra cerebral hemorrhage. 
  
. 
  
 
                                  
 
 
 
                   REVIEW OF LITERATURE 
HEMOGLOBIN 
 Hemoglobin contains heme, a cyclic tetrapyrole consisting of four 
molecules of pyrole linked by alpha methylene bridges. This planar network of 
conjugated double bonds absorbs visible light and colors heme bright red (12). 
 One atom of ferrous iron Fe2+ resides at the centre of the planar 
tetrapyrole. Oxidation and reduction of Fe and Cu in the cytochromes is 
essential to their biological function as carriers of electrons. By contrast, 
oxidation of Fe 2+ of hemoglobin and myoglobin to Fe3+ destroys their 
biological activity. They oxygenate instead of oxidizing (12). 
FREE RADICAL INJURY. 
 Peroxidation of lipids when exposed to oxygen is responsible for  damage 
to the tissues in vivo. This deleterious effects are caused by free radicals 
ROO*,RO*,OH* produced during peroxide formation from fatty acids. Lipid 
peroxidation is a chain reaction providing a continuous supply of free radicals 
that initiate further peroxidation (13). 
  
(1) INITIATION. 
  ROOH+METAL (
n
)  → ROO* + METAL (N-1) + H*   
                     X*+
 
RH →R* + XH 
 
(2).PROPAGATION. 
  R* + O2→ ROO* 
  ROO* + RH→ ROOH +R* 
(3).TERMINATION.
 
  ROO* + ROO*→ ROOR +O2 
  ROO* + R*→ ROOR 
  R*+ R*→ RR 
 Lipid peroxidation is a chain reaction with potentially devastating effects. 
To control and reduce peroxidation, humans have antioxidants. Chain breaking 
antioxidants are glutathione peroxidases that react with ROOH. In vivo the 
principle chain breaking antioxidants are Superoxide dismutase which act in the 
aqueous phase to trap superoxide free radicals 02-.Urate and Vitamin E act in 
the lipid phase to trap ROO* radicals. 
FREE  RADICALS. 
 Molecules or molecular fragments which have one or more unpaired 
electrons  are called free radicals (14). Any chemical moiety containing an 
oxygen atom with an unpaired electron in the outer orbital shell is called an 
oxygen free radical. Univalent reduction of oxygen or the action of ionizing 
radiation of oxygen results in the formation of oxygen free radical. 
Potentially cytotoxic reactive oxygen species are, 
O2
-
   - SUPEROXIDE OH* - HYDROXY RADICAL 
HO2* - HYDROPEROXYL ROO* - PEROXIDE 
H2O2  - HYDROGEN PEROXIDE O
-
 - SINGLET OXYGEN. 
 
 
 In the normal system, 2% of oxygen free radicals are produced by 
mitochondria due to inadequate utilization of oxygen. This may be produced 
more when the efficient functioning of electron transport is compromised (15). 
 Free radicals may react with membrane lipids by lipid peroxidation. Each 
lipid peroxide that is produced is itself a free radical and once produced,  
triggers a autocatalytic process as each lipid attack neighboring fatty acid to 
yield additional lipid peroxide products (16 , 17). 
 
 
BRAIN AS A TARGET OF FREE RADICAL INJURY. 
 Brain is especially vulnerable to the free radical injury because of high 
content of unsaturated fatty acids and relative deficiency of antioxidant 
mechanisms. Unsatturated fatty acids account for more than 20% of fatty acids 
in the body (18).Human brain has only 3% of total glutathione peroxidase of 
liver, completely devoid of non selenium containing enzymes. Catalase levels 
are only less than 1 % of liver and RBC. The vitamin E levels are also less than 
50 % of that of liver. On the other hand brain contains high levels of ascorbic 
acid (19). 
IRON AND THE FREE RADICALS. 
 In general iron in the human serum is bound to proteins in hemoglobin 
and myoglobin. About 2/3
rd
 of body iron is in the form of hemoglobin. To 
participate in free radical formation, iron must be liberated from the protein 
(18). The liberated iron catalyses the formation of free radicals by two reactions, 
1. Haber Weiss reaction and 2. Fentons reaction. 
Haber Weiss reaction. 
 Reaction of superoxide with hydrogen peroxide to produce highly 
reactive hydroxyl radical in the presence of iron (20). 
  O2
_ 
+ H2O2 →O2+OH
- 
+OH* 
Fenton’s reaction 
 Hydrogen peroxide in the presence of ferrous iron produces highly 
reactive hydroxyl radical (21). 
  H2O2 + Fe
2+→Fe3++OH* +OH. 
 Further more studies have shown that the catalyses of hydroxyl radical 
formation from the hydrogen peroxide requires Fe
2+
, and Fe
3+
 being ineffective 
(22). When iron forms complexes with di and triphoshate ester nucleotides ,Fe
2+
 
remains in a catalytically active state. Thus if iron is available for movement in 
to the cell, it may ligate with the di and triphosphate esters and is easily reduced 
by ascorbate to the ferrous form which is very effective in catalyzing hydroxyl 
formation from hydrogen peroxide (23). 
           In a large prospective study, Salonen & coworkers showed elevated 
serum ferritin consisted a strong risk factor for acute myocardial infarction . 
Stored iron in the form of ferritin is not essential for sustaining life or for 
preventing anemia, but when liberated, it can promote tissue injury by 
provoking iron mediated Fenton reaction (24). 
 The liberation of iron and heme compounds from hemoglobin following 
hematoma, hemorrhagic infarction, or head and spinal cord injury is a critical 
factor in the initiation of neuronal death (Braugher et al) (25). Ikeda et al 1989 
showed the iron chelator deferoxamine to be protective against cold induced 
brain edema (26, 27). Hall and braugher showed that 21 amino steroids 
specifically developed to quench iron induced free radical induction, 
ameliorated spinal cord and brain edema due to trauma. 
IRON METABOLISM 
 The iron absorption takes place largely in the proximal small intestine 
and is a carefully regulated process. For absorption, iron must be taken by the 
luminal cell. This process is facilitated by the acidic content of the stomach 
which maintains the iron in solution (28). At the brush border of the absorptive 
cell, the ferric iron is converted into ferrous iron by ferrireductase. Transport 
across the membrane is carried by divalent metal transporter (DMT 1).DMT1 is 
a general cation transporter. Once inside the gut cell, iron can be stored as 
ferritin or transported throughout the cell  to be released at the basolateral 
surface to plasma transferrin through membrane embedded iron exporter called 
ferroportin (29). 
 The function of ferroportin is negatively regulated by hepcidin, the 
principle iron regulating hormone (30). In the process of release, iron regulates 
with another ferrroxidase called hepahastin, which oxidizes the iron to the ferric 
form for transferrin binding. Once the iron bearing transferrin interacts with the 
receptor, the complex is internalized via clathrin coated pits and transported to 
an acidic endosome, where the iron is released at the low pH. The iron is made 
available for heme synthesis while transferrin receptor complex is recycled to 
the surface of the cell. 
SERUM FERRITIN: 
 Free iron is toxic to cells and the body has established an elaborate set of 
protective mechanisms to bind iron in various tissue compartments. Within cells 
iron is stored complexed to protein as ferritin or hemosiderin.Apoferritin binds 
to free ferrous iron and stores it in the ferric state .As protein accumulates 
within the cells, protein aggregates are formed called hemosiderin (31). 
 Under steady state concentrations, the serum ferritin levels correlate with 
the body iron stores. Thus the serum ferritin level is the most convenient 
laboratory method to estimate iron stores (32). 
 Adult males have serum ferritin values averaging 100mcg/l, while adult 
females have 30 mcg/l. 
 As the iron stores are  depleting, the serum  ferritin levels fall less than  
15mcg/l. Such levels are diagnostic of absent iron stores. 
 Ferritin is the key storage protein in the brain. Fully assembled ferritin 
contains 24 subunits of H and L chains. The H chain has ferroxidase activity 
and can convert ferrous iron to ferric iron thereby limiting the availability of 
ferrous iron to participate in the production of free radicals (33,34).   
IRON STORE MARROW IRONSTAIN Sr.FERRITIN  
(mcg/l) 
0 0 Less than 15 
1-300mg Trace to 1+ 15 -30 
300-800 2+ 30-60 
800 – 1000 3+ 60 -150 
1-2g 4+ More than 150 
Iron overload - >500-1000. 
 
IRON AND VASCULAR DISEASE 
 In 1981, JL Sullivan proposed the iron hypothesis, stating that increased 
incidence of coronary disease in men and postmenopausal women is due to 
increased body iron stores (35). Grobbee .et al. in a population based cohort 
study of 11,471 Dutch postmenopausal women concluded that higher serum 
ferritin concentrations in postmenopausal women are associated with increased 
risk of ischemic stroke (36). Iron plays a critical role in atherosclerosis by 
oxidizing LDL to form oxidized LDL which is highly atherogenic. It can also 
activate platelets via protein kinase C mechanism (37). 
 The role of iron in cardiovascular disease and carotid atherosclerosis has 
been proved by many independent investigations. In study of health in 
Pomerania SHIP, Birger wolf et al identified a relationship between serum 
ferritin levels and carotid atherosclerosis which was potentiated by LDL (38). 
Iron and CVA. 
 Iron induced brain damage has been extensively studied by A.Davlos et 
al. They showed elevated serum ferritin measured at the onset of symptoms 
increased the risk of progression to stroke by 33% , independent of other 
predictors of neurological outcome (39 ,40).They demonstrated that serum 
ferritin levels are stable during the 72 hours after the acute stroke and are 
unrelated to the other biochemical markers of stress reaction (41) and the 
relation between plasma ferritin and progressing stroke was independent of the 
ultimate infarct volume. So increased ferritin values predict early neurological 
worsening also in small cerebral infarcts.Blood ferritin is a reliable indicator of 
tissue iron and therefore might be a suitable index of availability of iron in the 
infracted area of acute stroke patients without infectious or inflammatory 
disease.Comparatively serum iron and transferrin saturation have a high analytic 
variability due to hemolysis and extensive day today variability (30 – 50 %) 
(42,43) 
 Coyle et al and others in various experimental works showed an 
interaction between iron and glutamate release and free radical injury and 
subsequent neuronal death. Intra ischemic glutamate release in penumbra cortex 
correlates positively with enhanced free radical activity during reperfusion after 
transient middle cerebral artery occlusion (44). 
 Huan Dong et al from Southern medical university, China studied the 
expression of H chain of ferritin in brain samples from 19 patients undergoing 
surgery for traumatic brain injury by RT-PCR, immunohistochemistry and 
Western blot. 
 They found that iron was overloaded and ferritin H chain was upregulated 
in human cortex after TBI. The enhanced expression of ferritin remained 
elevated for a long time till  48
th
 hour post injury. Experimental evidence also 
suggests that HO-1 was upregulated  and the increased HO-1 can accelerate 
heme degradation and can set in a vicious circle. Inhibition of HO-1 has been 
associated with attenuation of perihematomal edema volume in ICH (45). 
Serum ferritin and perihematomal edema volume. 
 Among other factors of morbidity and mortality in ICH, perihematomal 
edema volume also plays a significant role. In ICH the edema occurs in two 
phases. In the early phase, edema is due to the hydrostatic pressure of 
hematoma formation and clot retraction.The delayed phase is due to the 
hemolysis and neuronal toxicity in part mediated by iron. 
            In a retrospectively reviewed and prospectively collected clinical and 
laboratory data from 23 consecutive patients with acute spontaneous ICH, Manu 
Mehdiratta et al showed that delayed iron toxicity played a role in causing brain 
injury and edema formation after ICH (46).  
 Xi.G.et al infused lysed erythrocytes into the rat brain and found out 
marked edema formation within 24 hours. However when they infused packed 
cells, edema peaked on day 3 coinciding with the RBC lysis and release of Hb 
(47,48). 
 Savman et al. compared the level of non protein bound iron (NPBI) in the 
CSF of 20 preterm infants with intraventricular hemorrhage and 10 preterm 
control infants. They found out NPBI in 75% of the patients with IVH and 0% 
in control infants. The NPBI was found in very high levels in CSF from patients 
with IVH and also in those with white matter lesions and subsequent disabilities 
(49). 
 Manu Mehdiratta found little correlation between change in hematoma 
volume and corresponding relative edema volume between admission and day 
3.They concluded that perihematoma edema formation cannot be solely 
considered an epiphenomenon of hematoma growth (46). 
 Serum ferritin might be the suitable indicator of the availability of iron 
and ferritin in the area of ICH. After ICH when the blood leaks out of the blood 
vessels, ferritin at the hemorrhage site is partly derived from the serum as the 
blood serum separates from the clotted blood following clot retraction, thereby 
releasing its ferritin into the hematoma site. There is also indirect evidence to 
suggest that iron released from the lysed RBCs is likely influenced by serum 
ferritin levels. 
 Natalia Perez et al studied 92 consecutive patients with primary 
hemispheric ICH. They determined serum ferritin levels and other inflammatory 
markers. They found out 51 (55%) patients had poor outcome (Rankin score 
>2).Advanced age, high stroke scores, large hematoma volume, intraventricular 
extension, mass effect and high ferritin values at baseline were associated with 
poor outcome. The higher the ferritin quartile, the worse the Rankin scores. 
Ferritin levels remained stable for 72 hrs and did not correlate with acute phase 
reactants. They concluded that high ferrritn levels at admission are 
independently associated with poor outcome in patients with ICH and suggested 
the neurotoxic effect of increased body iron stores in patients with hemorrhagic 
stroke (49). 
Serum ferritin as an acute phase reactant. 
 Arola Armengou et al studied a group of 34 consecutive patients with an 
acute ischemic stroke of <8 hours duration. They collected blood samples at 
admission, 24 hrs, 48 hrs, and day 5 from symptom onset. They measured 
serum ferritin, cortisol, CRP, leucocyte count and plasma fibrinogen. Their 
study showed no statistical difference between the concentrations of ferritin at 
admission and those obtained before 48 hours. Whereas cortisol values 
increased significantly and CRP showed moderate increase after 24 hours. They 
confirmed serum ferritin concentrations are not associated with stress reaction 
and acute phase reactants in patients with stroke. 
 The nonsignificant rise in serum ferritin during the first 2 days after 
stroke is of insufficient magnitude to explain the large difference in ferritin 
levels between the patient with good prognoses and those with bad prognoses 
(50). 
 In a comparative study of serum ferritin and the acute phase reactants in 
patients undergoing minor and major surgery,  M.F Asalou et al, showed the 
ferritin levels rises only after 3 days of the inciting stress. The levels remain 
stable before 3 days of the surgery (51).  
INTRACEREBRAL HEMORRHAGE  
 Bleeding into the substance of the brain was recognized as a cause of 
stroke by Morgagni in1761. Cheyne wrote a treatise on apoplexy and coma in 
1812, in which he included examples of intracerebral hemorrhage (52). 
INCIDENCE AND EPIDEMIOLOGY 
Approximately 10% of strokes are caused by ICH.(53,54,55) .Populations 
with high prevalence of hypertension such as Asians and African Americans 
have a higher incidence of ICH. ICH affects a wide age range, with many 
examples in the seventh, eighth, and ninth decades of life.   Higher percentage 
of strokes in patients younger than 40 years are hemorrhagic, and ICH is also 
common during the later years of life. 
 
 
PATHOGENESIS 
 In the study conducted on autopsy specimen by Fisher (56), the 
hematoma contained a central mass of clotted blood surrounded by fibrin caps 
called globes. It represented the fibrin caps of small ruptured blood vessels 
surrounding the hematoma. 
 After ICH, as the hematoma expands, the surrounding small blood vessels 
break resulting in expansion of the hematoma. Slowly the hematoma grows like 
a snow ball.  The intracranial pressure slowly rises and the tissue pressure 
surrounding the hematoma also rises. Thus a new equilibrium is reached, 
bleeding stops and the hematoma stops growing. If the hematoma reaches the 
surface of ventricle it may decompress itself into CSF. 
SYMPTOMS 
 The symptoms of hemorrhage into the brain develop gradually because 
the blood is usually from small vessels and is released under capillary pressure. 
In contrast to SAH, ICH develops gradually during minutes or sometimes hours. 
 In larger lesions, there is a smooth gradual worsening of function 
followed by vomiting and headache. Some patients may develop further 
detoriation after two days of initial stabilization .It is due to development of 
edema around the hematoma. When a detailed history is possible, nearly all 
patients with ICH have had a gradual evolution of symptoms and signs some 
more rapidly evolving than others (57). 
Headache 
 As the brain parenchyma is pain insensitive, bleeding usually does not 
cause headaches. If the hematoma is near the surface of the brain as in case with 
lobar and cerebellar hemorrhage, the blood may irritate the meninges and cause 
headache and it may accompany meningeal signs (58).However headache is 
usually absent or minimal in small lesions. Patients with small, deep hematomas 
often never develop headache during their course of illness.(57). 
 Headache was not an invariable symptom in the 60 HSR patients with 
ICH. Headache was described in only 17 patients (28%) near the onset of 
neurologic symptoms (59). Another seven patients (12%) noted headache later. 
Twenty-four patients (40%) had no headache at any time during their ICH. The 
12 stuporous or comatose patients (20%) could not provide data regarding 
headache. Headache was much more frequent with larger lesions, and was often 
absent or minimal in patients with small lesions. 
Decreased Level of Consciousness 
 Decreased level of consciousness has been found to be an 
important prognostic sign in nearly all series of ICH patients (60). Early 
reduction of consciousness is not an invariable accompaniment of ICH. When it 
occurs, however, it has an ominous prognosis. Loss of consciousness only 
occurs in patients with large hemorrhages and with brain stem involvement. It is  
either due to involvement of reticular activating system or due to increased 
intracranial pressure.  
Vomiting 
 Vomiting is more common in ICH than any other cause of stroke and is 
an important sign. It is caused by increased intracranial pressure or due to 
distortion of 4
th
 ventricle as occurs in cerebellar hemorrhage. In posterior 
circulation hemorrhages, more than 50 % of the patients vomit. It reflects the 
involvement of vestibular nuclei or the vomiting center in the floor of the fourth 
ventricle (61). Patients with cerebellar hemorrhage almost always vomit early in 
their clinical course. In contrast, fewer patients with hemispheric infarcts vomit. 
Seizures 
Seizures are not common during the acute phase of a stroke, but are 
slightly more frequent in ICH  than other stroke types, except embolism. 
Among three series of patients with spontaneous  Nontraumatic ICH, 12.5%,  
15.4%,  and 17% of patients had seizures during their early course (62, 
63,64).Lobar hemorrhages, slit-like hemorrhages situated near the gray-white 
junction of the cortex, and putaminal hemorrhages that undercut the cerebral 
cortex are especially epileptogenic (65). 
Other Symptoms and Signs 
Neck stiffness is found with caudate, thalamic, and cerebellar 
hemorrhages (66,67).Fever is relatively common, but is often related to 
infectious complications, such as pulmonary and urinary tract infections. 
Subhyaloid retinal hemorrhages, common in SAH, are rare in ICH, unless the 
hematoma has developed rapidly and is large (68). Cardiac arrhythmias and 
pulmonary edema develop in some patients with ICH, and are usually attributed 
to changes in ICP and catecholamine release, a similar pathogenesis to that used 
to explain cardiac findings in patients with SAH. 
ETIOLOGIES 
Hypertension 
 Hypertension is the most common cause of ICH. But there may not be 
malignant range of elevation in blood pressure.  ICH may be the initial 
presentation of hypertension. In most patients presenting with ICH, it is difficult 
to ascertain  whether  the elevated blood pressure is a due to Cushing response 
or the patient was hypertensive. 
The occurrence of ICH in hypertension is biphasic, after developing 
considerable wear and tear on penetrating brain arteries, both during the early 
and late stages (69). During the early stages of systemic hypertension, the 
capillaries are exposed to the high pressure and consequently break and bleed. 
As the blood vessels are chronically exposed to increased blood pressure, 
degenerative changes develop in the vessel wall in the form of lipohyalinosis 
and milliary Charcot Boucher aneurysms. In the later stages, these 
degenerations cause arteriolar rupture and ICH.  
 Cole and Yates examined the brains of 100 hypertensive patients and 100 
normotensive controls (70). All 13 patients with ICH had micro aneurysms and 
were hypertensive. Among 63 patients with microaneurysms, 46 patients had 
hypertension recognized during life. The age distribution of micro aneurysms 
was also interesting. Among 21 hypertensive patients younger than 50 years, 
only two patients had micro aneurysms, whereas 71% of hypertensive patients 
in the 65- to 69-year age range had microaneurysms. 
 Micro aneurysms are often surrounded by hemosiderin-laden 
macrophages, indicating previous leakage. The lesions are most common in 
penetrating arteries that supply the basal ganglia, thalamus, pons and 
cerebellum, and arteries supplying the gray-white matter cortical junctions of 
the hemispheres. The same arteries that bear micro aneurysms also contain foci 
of lipohyalinosis and fibrinoid degeneration, which explains the dictum that 
ischemic lacunes have the same relative distribution as hypertensive ICH.  
A relationship between iris aneurysms and cerebral micro aneurysms 
exists because rabbits with experimentally induced hypertension develop iris 
aneurysms approximately proportional to their development of cerebral 
microaneurysms (71). 
Takebayashi et al in a study of surgical specimens of acute ICH showed 
that the penetrating arteries were the common site of bleeding but it had little 
relation to the micro aneurysms (72). Degenerative lipohyalinotic changes were 
present in the broken and adjacent arteries. Degenerative changes caused by 
aging and hypertension can predispose to ICH, but micro aneurysms may not 
often be the bleeding lesion. 
 Acute changes in the blood pressure without preexisting chronic 
hypertension can cause rupture of penetrating arteries and can predispose to 
ICH. In a clincopathalogical study of 218 patients, Bakemura estimated the 
prevalence of hypertension in patients died of ICH by using heart weight as an 
evidence of hypertension. He found out that only 46% of fatal ICH patients had 
evidence of moderate to severe hypertension and left ventricular hypertrophy. 
(73). 
Brott and colleagues in a retrospective study of hospital records of 
patients with ICH admitted during 1 year period found out that only 45 % had 
history of chronic hypertension. Another 12% without a history of hypertension 
had left ventricular hypertrophy.  So they concluded that only 50 % of ICH can 
be attributed to chronic hypertension (74).However they found out that the 
locations of bleed was similar to that occurring in chronic hypertension. The 
hypertension recorded at the time of admission is probably an acute event which 
led to break down of unprotected capillaries and therefore was actually 
hypertensive hemorrhages. Another example of acute hypertension producing 
ICH is due to recreational drug usage like cocaine and methamphetamine which 
have strong symphathomimetic effects. 
Patients have also developed ICH after sudden augmentation of cerebral 
blood flow, either locally to one hemisphere, as in the circumstance of ICH after 
carotid endarterectomy (75)  or systemically, after correction of congenital heart 
defects or cardiac transplantation in the young (76,77). ICH has also been 
reported to develop during recovery from migraine. Intense vasoconstriction 
leads to diminished flow and, perhaps, ischemia to local blood vessels. 
Reperfusion then leads to ICH in the zone of prior vascular damage (78). A 
similar mechanism probably underlies most examples of hemorrhagic infarction 
caused by brain embolism.  
The most common locations for hypertensive ICH in various series are: 
putamental-lateral ganglionic (25%-40%), thalamic (15%-30%), lobar (10%-
30%), caudate (5%-10%), pontive (5%-10%), cerebellar (5%- 10%), and 
intraventricular (0% -5%). In postmortem analyses, an increasing number of 
patients dying of lobar brain hemorrhages are found to have an unsuspected 
amyloid angiopathy.  
Bleeding Diathesis 
Coagulopathies whether acquired or inherited can predispose to 
intracerebral bleeding which is accentuated by hypertension. So far treatment 
with anticoagulation either with heparin or warfarin is the leading cause of ICH 
in patients with coagulopthy overall. .However it should be noted that ICH 
develops in only small number of patients who are on anticoagulation. Askey et 
al reported that in a series of 1626 patients on long-term anticoagulation only 30 
had ICH, of which two thirds are fatal. The most important for ICH is the 
increasing prothrombin time beyond therapeutic range. Some hemorrhages 
occur even when the international normalized ratio is in the therapeutic range. 
As with other etiologies of ICH, hypertension aggravates the tendency to bleed 
intracranially(79).  
Kase et al found three characteristic feature of anticoagulant induced 
bleeding. They are 1. Hemorrhage often develops gradually and insidiously 
during many hours, or even days;( 6 of 14 patients with anticoagulant-related 
ICH in one series had an insidious clinical course). 2. The cerebellum and 
cerebral lobes are involved more frequently than in hypertensive ICH. 3. A high 
morbidity and mortality rate exist (15 of 24 patients died), and only patients 
with smaller hematomas (less than 30cc volume) had a favorable chance for 
survival; only 1 of 24 patients with ICH had bleeding elsewhere (80,81).  
Treatment of anticoagulant-related ICH is a difficult task because most of 
the patients require anticoagulation as a prophylaxis against ischemic stroke. 
Patients with prosthetic heart valves, rheumatic mitral stenosis, or atrial fi 
brillation have a high risk for cerebral emboli without warfarin therapy. Because 
of their size and location in the surgically accessible cerebellum and cerebral 
lobes, many eventually require life-saving surgery. The initial clinical diagnosis 
may also be difficult in the group on warfarin for stroke prophylaxis because the 
first reaction to the neurologic symptoms is to predict that the patient had an 
ischemic stroke despite the treatment. The following general principles can be 
applied in ICH related to anticoagulation. 
1. If a patient on anticoagulants develops neurologic symptoms, the cause 
is anticoagulant related hemorrhage until proven otherwise. 
2. If anticoagulant hemorrhage is verified, immediately vitamin K, factor 
VIIa, or fresh frozen plasma should be administered. Aggressive measures 
should be taken to stop bleeding and the risk of embolism should not be a 
deterrent. 
   Although no formal prospective studies clarify the optimal time for 
restarting anticoagulants after ICH in patients who require long-term treatment, 
a retrospective analysis found that after 10 to 14 days, recurrent ICH did not 
develop (81). The decision on if and when to restart anticoagulants depends on 
the risk of embolization from the donor source (atrial fibrillation, prosthetic 
heart valves, etc.) and the risk of further intracranial bleeding. Studies seem to 
show that the risk of embolization while anticoagulants are stopped is less than 
predicted and the risk of hemorrhage if anticoagulants are reintroduced is also 
less than expected.  When the indication for anticoagulation is relative or 
questionable, it is probably best to discontinue anticoagulants, perhaps using 
platelet antiaggregants instead.  
Leukemia, hemophilia, thrombocytopenia, von Willebrand disease, and 
disseminated intravascular coagulation are other important causes of ICH. 
Intracerebral hemorrhage can occur after thrombolysis for either ischemic stroke 
or myocardial infarction. The ICH developing in these settings is usually large 
and fatal (82).In this circumstance, hematomas usually begin within the region 
of brain infarction. 
Drugs 
Many abused substances are capable of causing stroke. It should be 
thought as a cause in young patients with ICH in whom other causes except 
trauma and arteriovenous malformations are less common. (83). 
In amphetamine (speed), hemorrhages develop within few minutes of 
drug use. The most frequent presenting symptoms are headache, confusion, and 
seizures. Because of the coexistent edema and diffuse vasculopathy, there will 
be less focal signs inspite of large volume of bleed. When first examined by 
physicians, most patients with amphetamine hemorrhage do not have signs of 
sympathetic over activity, such as hypertension, tachycardia, or fever. 
 Citron et al studied 14 drug abusers, almost all admitting use of 
methamphetamine, among other drugs. At necropsy, a fibrinoid necrosis of the 
media and intima of small- and medium-sized arteries existed, resembling 
polyarteritis nodosa (84). Rumbaugh and colleagues studied the angiographic 
features of a group of methamphetamine abusers and noted beaded arteries with 
segmental constriction and dilatation of intracranial arteries. A potent solid form 
of d-methamphetamine base that can be smoked is now peddled in the streets 
(known as ice). This form is more potent and rapid acting. Angiography has 
often shown striking abnormalities in chronic amphetamine users and other 
patients with amphetamine-related ICH. Most common are segmental areas of 
constriction, irregularity, and occasionally fusiform dilatation.  The focal 
vascular abnormalities usually emphasize superficial cortical arterial branches 
and are often referred to as beading. At times, the changes disappear on 
subsequent angiography. Unfortunately, these arteriographic changes have often 
been falsely attributed to arteritis. Beading and areas of vasoconstriction and 
dilatation is a non-specific sign and more often than not is not due to arteritis 
(85). 
Cocaine is a potent narcotic that can be taken in many ways. Cocaine 
hydrochloride is usually snorted nasally. Cocaine hydrochloride is mixed with 
ammonia or baking soda to produce crack cocaine. It is precipitated as alkaloid 
cocaine after mixing with alkaline solution and is inhaled. Crack cocaine is 
absorbed quickly, reaching the brain in less than 10 seconds. Cocaine 
hydrochloride can be taken in a variety of ways—orally, vaginally, rectally, 
sublingually, nasally, and by subcutaneous, intramuscular, or intravenous 
injection. Cardiovascular effects begin immediately after use and consist of an 
increase in pulse, blood pressure, temperature, and metabolism. The pressor 
effects of cocaine are similar to those of amphetamine and are probably 
mediated through a peripheral catecholamine mechanism. 
    The most common location of cocaine related ICH was lobar (57%). In 
others, the bleeding often involved deep structures known to be frequent sites of 
hypertensive ICH. In contrast to amphetamine related ICH, there is increased 
frequency of underlying vascular malformations in cocaine related ICH. 
Cocaine can cause extreme elevations of blood pressure and patient may 
develop cerebral edema and hypertensive encephalopathy in addition to ICH 
(86). 
 The other drugs that has a potential to cause ICH include phencyclidine 
PCP (angel dust), LSD and mescaline (87). They have sympathomimetic and 
vasoconstrictive properties but less implicated in causing ICH than cocaine and 
amphetamine.  Other drugs causing ICH are Pentazocine and pyribenzamine 
(―T‘s and blues‖) or methylphenidate.  
It is important to note that some over the counter medications that are 
sold as cold remedies are occasionally implicated in causing ICH.Phenyl 
propanolamine which has alpha adrenergic activity has been implicated in 
causing ICH among its users (88).The dose of PPA in weight control drugs was 
higher than normally prescribed. In some patients there is an idiosyncratic 
reaction to the usual dose of PPA.Most often PPA related ICH occurs in patients 
taking it as over the counter drug for weight control. Very handful of cases is 
reported after taking cold remedies .So PPA has been removed from cold 
remedies in most of the countries. Angiographic changes similar to that of 
amphetamine has been described in long-term PPA users. Most of them cleared 
after abstinence for one month. (88). 
Examples of putative PPA-related hemorrhages are difficult to evaluate. 
In some cases, use of diet pills was surely incidental, and in other patients, other 
multiple drugs and risk factors coexisted. In several patients, ICH occurred a 
few weeks postpartum, a time of vulnerability for spontaneous vascular 
complications. Although PPA has been shown to be associated with ICH in 
experimental animals and humans, reactions to PPA compounds are often 
idiosyncratic. A risk of ICH clearly exists for those who use PPA in a higher-
than suggested dose. Prior hypertension; additional use of alcohol, coffee, or 
caffeine; concomitant use of monoamine oxidase inhibitors; and use during the 
postpartum period increase the risk of hemorrhage after PPA ingestion (89).  
The phosphodiesterase inhibitors such as sildenafil, vardenafil and 
tadalafil were occasionally implicated in ICH.However it is difficult to evaluate 
whether the drug is causative or the increased blood pressure response that 
occurs during sexual intercourse caused the bleed (90). 
Cerebral Amyloid Angiopathy 
Congophilic or cerebral amyloid angiopathy (CAA) was recognized by 
Zenkevich as a potential cause of ICH,  But Jellinger is probably most 
responsible for bringing this disorder to the attention of the neurologic 
community. There is a striking female prediliction. It has  been recognized 
increasingly as a cause of ICH in elderly patients . Higher the age, higher the 
incidence of cerebral amyloid angiopathy (91). 
It usually affects the small arterioles and arteries supplying the 
leptomeninges. The affected vessels show characteristic staining pattern with 
special stains. They stain positively with periodic acid Schiff and show acellular 
hyaline material. On staining with congored and when looked under polarized 
light, it shows characteristic apple green birefringence. The walls may seem 
duplicated or split. They are occasionally found in the cerebellum. Hemorrhages 
may be quite large and are often multiple. Some patients have recurrent ICH or 
SAH in different lobar sites, a finding in an elderly person that is virtually 
diagnostic of CAA (92).  
In MRI imaging of the brain with echo planar technique, small  scattered 
areas of old bleeds called micro bleeds are seen .These are predictive of future 
hemorrhages in CAA affected patients. Some patients may have Binswanger 
like picture showing diffuse white matter disease. 
In older patients because of brain atrophy, the excess blood can be 
accommodated inside the cranial cavity without much increase in intra cranial 
pressure. So the symptoms are insidious without much head ache or vomiting. 
Trauma 
Trauma is one of the important causes not only in young but also in old 
age group. Often the history of trauma is not present or trivial. In some patients 
there may be retrograde amnesia to that event. In all patients, it is worthwhile to 
search for lacerations and bruises to find signs of trauma. Traumatic ICH is 
usually accompanied by contusions that are located in frontal and temporal 
poles as they hit upon the bony prominence. The contusions are often multiple. 
Occasionally hemorrhages may develop at the site of contusion after some 
period of time when the edema subsides. It is called spät hemorrhage (94). 
SIGNS AND SYMPTOMS OF ICH AT COMMON LOCATIONS: 
Keys to localization of ICH follow: 
1. Motor signs—quadriparesis, hemiparesis, or no paresis 
2. Pupillary function—asymmetry, size, and light reaction 
3. Extra ocular movements—supranuclear, nuclear, internuclear gaze palsies 
4. Gait abnormalities, especially ataxia 
Hemorrhages of the Lateral Basal Ganglia, Putamen, and Internal Capsule 
The hemorrhage caused by hypertension is usually located in the lateral 
portion of basal ganglionic capsular region. (94) As the bleed usually starts at 
the putamen, they are commonly called putaminal hemorrhages. The clinical 
features include contra lateral hemisensory loss, contralateral hemiplegia and 
ipsilateral deviation of eyes.  
The hematoma may undercut the cortical connections, causing 
disconnection syndromes and result in transient cortical abnormalities. If the 
hemorrhage is in the left putamen, non fluent aphasia with preserved repetition 
occurs. Right sided lesions result in contralateral visual neglect, motor 
impersistance and constructional apraxia. However these abnormalities are 
transient and usually of smaller magnitude as compared to the cortical infarct or 
hemorrhage. 
If hematoma is large, patient become stuporous. As the lesion enlarges 
there is increasing depth of coma and the ipsilateral pupil becomes constricted 
followed by dilatation. The ipsilateral plantar becomes extensor. Bilateral 
horizontal gaze palsy develops. Development of these signs carries grim 
prognosis. (95) 
Caudate Hemorrhage: 
Hemorrhage into the caudate nucleus accounts for approximately 7% of 
ICH. The blood discharges into the adjacent lateral ventricle resulting in its 
dilatation. So the signs and symptoms of increased intracranial tension develops 
earlier in caudate hemorrhages. The blood may track toward internal capsule or 
into the hypothalamus. The symptoms include headache, vomiting, depressed 
consciousness and neck stiffness. If the hematoma is large, there may be 
contralateral hemiparesis, conjugate deviation of eye towards same side with 
contralateral gaze palsy. Patient may develop ipsilatral miotic pupil with or 
without Horners syndrome. There is minimal or absent symptoms and signs 
(96).  
Thalamic Hemorrhage 
 In contrast to caudate or putaminal bleeds, there is very little motor 
paralysis in thalamic hemorrhage. It is because  most of the pyramidal fibers are 
anterior to the hematoma and are spared or little affected. There are prominent 
sensory symptoms in the contralateral side of the body (97).  
The key features of thalamic hemorrhage are the eye signs. The 
characteristic oculomotor abnormalities in patients with thalamic hematomas 
are as follows: 
1. Paralysis of upward gaze, often with one or both eyes resting downward 
2. Hyperconvergence of one or both eyes, with a combination of these findings 
giving patients the eyes inward at the tops of their noses 
3. Ocular skewing, in which one eye rests below the other, with this divergence 
in vertical eye position remaining constant in gaze in all directions 
4. Eyes gazing the wrong way resting toward the opposite side, 
5. Disconjugate gaze, with limited abduction of one or both eyes (so-called 
pseudo sixth nerve paresis), failure of ocular abduction caused by visual fixation 
of the adducted eye, and increased convergence vectors neutralizing abduction-
not caused by involvement of the sixth nerve. 
These oculomotor abnormalities are caused by direct extension of the 
hematoma to the diencephalic mesencephalic junction or compression of the 
quadrigeminal plate region by the thalamic hematoma. 
 In thalamic hemorrhage, the pupils are usually small and react poorly to 
light because of interruption of the afferent limb of the pupillary reflex arc. 
Patients with large left thalamic hemorrhages often have an unusual aphasia 
(99). After beginning a conversation almost normally; patients may lapse into a 
remarkable fluent aphasia, with many jargon of nonexistent words and poor 
communication of ideas. In contrast to patients with Wernicke‘s aphasia, 
comprehension of spoken language is good.  
Overall the prognosis is worse when compared to hemorrhages in other 
areas. Also the extension of the hematoma does not correlate with the mortality 
or morbidity. But the early occurrence of decreased alertness and increased 
sleepiness does not signify a poor prognosis as in other cases. It is due to the 
involvement of rostral reticular activating system. 
Lobar Hemorrhages 
Bleeding under the greywhite junction usually track along the white 
matter tracts .When the blood is absorbed , it results in a slit like shape giving 
the lesions the name ―slit hemorrhage.‖ Undercutting of the cortex can be 
epileptogenic, causing repeated focal seizures of limited duration (99). It is 
essential to diagnose subcortical bleeds because, the slit hemorrhage may be 
mistaken for infarct and antiplatelets may be erroneously prescribed. Due to its 
superficial location, subcortical hemorrhages are accessible for surgical 
drainage. Most of the lobar hemorrhages are due to AVMs, CAA, or cavernous 
hemangiomas. Hypertension is also an important cause of lobar hematomas. 
The parietal and occipital lobes are affected more often than the frontal and 
parietal regions. 
 Symptoms and signs depend on the lobes affected, as follows: 
1. Frontal hematomas:  
Far anterior lesions usually cause abulia. Patients appear apathetic and 
have reduced spontaneity, prolonged latency in responding, and short, terse 
replies. If the lesions extend deeply or toward the precentral gyrus, conjugate 
eye deviation toward the side of the hematoma and contralateral hemiparesis are 
found.  
2. Paracentral hematomas:  
 Lesions near the central sulcus produce contralateral motor and sensory 
signs, sometimes with aphasia if the lesion is in the left hemisphere. 
3. Parietal hemorrhages:  
 Parietal hemorrhages are usually accompanied by contralateral 
hemisensory loss, with neglect of the contralateral visual field. The limbs 
contralateral to the hemorrhage are often uncoordinated. Aphasia and disorders 
of reading, writing, and arithmetic functions are present when the lesions 
involve the left inferior parietal lobule. Patients with right inferior parietal 
hematomas have defective drawing and copying and may have difficulty with 
visual spatial functions. 
4. Occipital hematomas: 
  Occipital hemorrhages cause a severe contralateral hemianopia, often 
with slight contralateral hemisensory or motor signs and visual neglect. 
5. Temporal-lobe lesions:  
 Temporal-lobe lesions often cause agitation and delirium. Wernicke type 
aphasia accompanies left temporal lesions. Temporal-lobe hematomas are 
particularly likely to swell and may cause herniation without preceding 
hemiparesis. Brainstem compression may develop insidiously, with deepening 
stupor. An ipsilaterally dilated pupil follows. Lobar hematomas are usually 
smaller in volume than deep lesions and have a lower mortality rate. The 
functional outcome in patients with lobar ICH is also generally better than other 
forms of ICH. The exception to good outcome is the occurrence of lobar 
hemorrhage in patients taking anticoagulants. Anticoagulant hemorrhages have 
a predilection for the cerebral lobes and the cerebellum, and often gradually 
increase in size. The diagnosis of lobar hemorrhage is often quite difficult 
without CT or MRI. Because of the higher incidence of vascular malformations 
and other bleeding lesions in patients with lobar hematomas, angiography is 
often indicated, especially in patients who are young and  normotensive. 
 
Primary Intraventricular Hemorrhages  
 Primary intraventricular hemorrhages are rare in adults. Hemorrhage into 
the ventricle occurs when an adjacent locus discharges the blood into the 
ventricular system. Caudate and thalamic hemorrhages are most common to 
discharge into the ventricles. (100). 
 In children most common cause of intraventricular hemorrhage is 
choroidal vascular malformations. As bleeding occurs the AVM are destroyed 
by themselves.   
  If the blood distends both the ventricles, symmetric hyper-reflexia and 
extensor plantar responses occur. Also at times, the bleeding is primarily into 
one lateral ventricle, and asymmetric focal signs may predominate. Decreased 
consciousness always occurs in IVH. The blood in the ventricular cavity can be 
aspirated using neurosurgical techniques. 
Pontine Hemorrhage 
 Primary brainstem hemorrhages are located most often in the Pons. 
Midbrain and medullary hemorrhages are rare and when present, are usually 
caused by blood dyscrasias and vascular malformations.  
 Düret hemorrhages are pontine hemorrhages that are secondary to rapidly 
rising intracranial pressure. Raised ICP, especially if it develops quickly, 
frequently causes secondary lesions, so-called Düret hemorrhages. Primary 
Pontine hemorrhages usually begin in the center of the Pons at the tegmental-
basal junction. These hematomas grow quickly and assume a round or oval 
shape, usually destroying the center of the tegmentum and base of the Pons. 
Blood may dissect rostrally into the midbrain, but rarely extends caudally into 
the medulla. Hematomas frequently dissect into the fourth ventricle. Signs 
accompanying large medial pontine hematomas include (1) quadriparesis, often 
with limb stiffness and rigidity; (2) coma; (3) absent horizontal eye movements; 
(4) small but reactive pupils; and (5) rapid or irregular respirations.  Vertical 
reflex eye movements are preserved unless the lesion extends rostrally into the 
midbrain. In some patients, the eyes spontaneously and repeatedly bob 
downward. Hyperthermia is sometimes noted. 
Cerebellar Hemorrhages 
           Approximately 10% of ICH occurs in cerebellum. As it is a common site 
of hypertensive bleed, it is also a common site of anticoagulant related bleed. A  
study series by Toyada et al of 327 patients with ICH, 38 patients (12%) had 
their hemorrhage located in the cerebellum. Among them 75% were due to 
warfarin therapy. (101). 
 The site of bleed is usually the dentate nucleus due to rupture of distal 
branches of posterior inferior cerebellar artery and superior cerebellar artery. 
The involvement of brainstem is distinctly uncommon but it may be compressed 
by the hematoma from above. 
 Cerebellar hemorrhage is surgically amenable to evacuation and 
potentially disastrous if left untreated because the  sudden increase in the 
intracranial pressure may lead to herniation and sudden death. 
  The most consistent symptom is inability to walk. Few patients may find 
it difficult to even sit or stand and may lean toward the side of lesion. Vomiting 
is frequent owing to the structural distortion of the vomiting centre. Occipital 
headache is also common. Dysarthria, hiccups, and tinnitus occur, but are less 
common .Loss of consciousness occur little late along the course but if it 
occurs, it carries poor prognosis.  
  Other Neurologic signs include (1) an ipsilateral abducens or gaze palsy 
toward the side of the hematoma; (2) small pupils, with the ipsilateral pupil 
slightly smaller; (3) rebound overshoot of the rapidly elevated ipsilateral arm; 
and (4) gait ataxia. Hemiparesis rarely occurs in patients with cerebellar 
hemorrhage, but cerebellar lesions do produce an apparent asthenia or slowness 
of the affected limbs. The deep tendon reflexes are symmetrically exaggerated 
with a normal plantar response. Typical pendular knee jerk occurs. The other 
signs of cerebellar incoardinaton are rare. 
 The signs of brain stem compression are often present in large cerebellar 
hematomas. Even though coma is not present on admission these patients 
relatively have poor prognosis without surgical intervention. In a retrospective 
analysis of patients with acute cerebellar hemorrhage Brennan et al found out 
that in patients with  signs of brain stem compression 80% rapidly developed 
coma .About 25% of these patients slipped into coma within 3 hours of 
admission.(102). Only 20% had uneventful recovery. 
 In the series of Fisher et al  only  2 of 18 patients had a benign course. 
The other 16 patients developed coma, usually within a few hours. 
 Medullary compression causes vasomotor disturbance and respiratory 
arrest. If they are not intervened promptly they invariably die of brain stem 
compression.In contrast to bleeding into cerebellar lobes, vermian hemorrhages 
are a rare entity. It causes usually sudden death.  
 The outlook of smaller cerebellar hemorrhage is excellent and recover 
with very little residual deficit. Even in larger hematomas, if surgical 
intervention is undertaken before the event of reduced consciousness, the 
recovery is usually good (103).  
  
 
 
DIAGNOSIS, PROGNOSIS, AND TREATMENT 
 Diagnosis 
 The bedside diagnosis of ICH is usually made without difficulty in 
patients with symptoms such as headache and vomiting alongside slowly 
progressing, non fluctuating neurological deficit. Underlying predisposing 
factors such as hypertension, bleeding diathesis, drug abuse etc. helps in 
increasing diagnostic accuracy. 
  Non enhanced Computed tomography of brain is invaluable in the 
diagnosis of ICH. Acute blood provides dense contrast in the CT. Serial CT 
scans can be used to assess the progressing neurological deficit to rule out 
expanding hematoma.  (104). 
 In CT-angiography, the presence of central enhancement within the acute 
ICH, called  spot sign has been purported as an predictor of hematoma 
expansion   ( 105). 
 The age of the bleed can be assessed on the basis of characteristic 
features on the CT or MRI pictures.  Initially hematomas show smooth borders. 
In the first 48 hours the hematoma are partially liquid thereby demonstrating a 
fluid level.  The edema surrounding the hematoma produces an area of 
hypodensity around the hematoma for the first 3 days or longer. During the first 
few days there is considerable mass effect produced by the hematoma and 
edema. As the blood gets absorbed, the hematoma acquires an irregular outline 
which can be enhanced by contrast administration. This process starts in the 
periphery. There is reduction in the edema during this period. The blood in the 
ventricles disappears by 5 weeks. By 9 weeks, only a local circumscribed slight 
hypodensity remains.  
 The CT is sensitive for acute hemorrhage but MRI is much more sensitive 
for chronic lesions.Acute hematomas are isointense or hypointense on T1-
weighted scans, sometimes with a darker hypointense rim, and they are bright 
and hyperintense on T2-weighted images. Later, the center of the hematoma 
appears dark on T2 and is surrounded by a bright rim. Chronic hematomas are 
bright on T2-weighted images (106).  
 Angiography is generally unnecessary unless the lesion is in an unusual 
locus or the patient has no risk factors for hemorrhage, such as hypertension or 
bleeding diathesis. Catheter subtraction angiography is used to show AVMs or 
aneurysms that might have caused ICH. Angiography can also suggest the 
likelihood of hematoma enlargement. Extravasation of contrast during 
angiography correlates well with subsequent enlargement of the hematoma and 
poorer outcome (107). MR and CT angiography can be used in a similar 
fashion.  
 
Prognosis 
 The three most important predictors of outcome after ICH are size of 
hemorrhage, site of bleeding and state of consciousness of the patient at 
presentation. Hemorrhage expansion also indicates a worse prognosis when the 
hematoma attains a large size. Size and locale of the lesion on brain imaging 
scans renders very useful prognostic information. In putaminal hemorrhages, 
lesions larger than 140 mm2 in one slice have a poorer outcome. In thalamic 
hemorrhage, lesions larger than 3.3 cm in maximal diameter have a poor 
prognosis, as do cerebellar lesions larger than 3 cm. 
  In six additional studies, large-volume hematomas were associated with 
a poor outcome. Pulse pressure, admission blood pressure, and level of 
consciousness, as measured by the Glasgow Coma Scale, are also important 
prognostic variables (108). 
  High systolic, mean blood pressure, and pulse pressure correlate with 
poor outcome. The presence of hydrocephalus in patients with supratentorial 
hemorrhages is also an adverse prognostic sign (109).  
  In the chronic phase, if the patient with ICH  has survived, the prognosis 
for recovery is actually much better than brain infarcts of similar size and 
location. Hematomas have dissected and separated the cerebral cortex and other 
brain parts, but usually the surrounding cortex is preserved. In contrast, infarcts 
leave dead, nonfunctioning cortex when they heal. Unlike SAH, recurrence of 
ICH during the acute illness is rare. These simple facts dictate the approach to 
ICH treatment-that is, aggressively try to limit the expanding hematoma to 
prevent death and late morbidity. 
Treatment 
 The medical treatment is aimed at reducing the chance of hematoma 
expansion and reducing the cerebral edema and intracranial tension. Increased 
ICP causes decreased responsiveness and hypoventilation; in turn, 
hypoventilation causes a low arterial oxygen tension and high carbon dioxide 
tension, which lead to vasodilatation and further increase in ICP. Maintenance 
of a good airway and mechanical hyperventilation can reverse the process and 
quickly lower ICP.  
 Control of systemic blood pressure helps stop intracranial bleeding, but 
must be done cautiously. In some patients with ICH, systemic blood pressure is 
further increased to ensure adequate perfusion of the brain. Increased ICP 
causes increased venous pressure, so elevated arterial pressure is needed to 
overcome the increased venous pressure to perfuse the tissues. Overzealous 
lowering of blood pressure can lead to under perfusion and clinical 
deterioration. Blood pressure should be lowered quickly, but not to hypotensive 
levels. Patients must be watched carefully during the treatment. Guidelines from 
the Stroke Council of the American Heart Association recommend maintaining 
the mean arterial pressure below 130 mm Hg (110).   The perihematomal 
edema volume peaks during the third or fourth day after bleeding. The release 
of iron-containing breakdown products of hemoglobin likely contribute to the 
development of edema. Elevation of the head of the bed, hyperventilation, 
temperature control, and ventricular drainage have also been used to control 
increased ICP (111).Few data exist, however, about the effectiveness of these 
strategies. Concern exists that hypertonic agents could diffuse into the ICH and 
cause a secondary increase in volume of the hematoma because of ingress of 
fluid.  
    Langfitt noted that mannitol and forced hyperventilation were effective 
in reducing ICP in a group of patients with ICH. Poungvarin et al studied the 
usefulness of dexamethasone treatment in patients with supratentorial ICH in a 
double-blind randomized trial. They found that it did not improve mortality; and 
infections and diabetic complications were more often found in the 
corticosteroid-treated group (112).  
 When considering surgery and other therapies, hematomas, in practice, 
can be divided into the following three main groups: 
1. Massive, rapidly developing lesions that effectively kill or devastate patients 
before they reach the hospital. For these lesions, little can or should be done. 
2. Small hematomas, from which the patient will make an excellent spontaneous 
recovery. Treatment consists of controlling the etiologic factors, such as 
hypertension, to prevent recurrences. 
3. Medium-sized hemorrhages (hematoma volumes between the two extremes) 
with developing mass effect after the patient reaches the hospital. Within this 
third group, medical measures and surgery are most helpful.  Because 
hematomas represent the development of so-called benign masses, the logical 
treatment for life-threatening lesions is surgical drainage. The factors outlined 
in the following should be considered in deciding on surgical therapy. 
Size 
Hematomas larger than 3 cm in their widest diameter have a higher 
mortality and a more delayed recovery rate than smaller lesions. Thus, the larger 
the lesion on CT, the more logical its drainage would be. 
Location 
 Some hematomas are more accessible surgically, such as those in the 
cerebellum and cerebral lobes. Although putaminal hemorrhages can be drained 
through the sylvian fissures and insular cortex, large left basal-ganglionic 
hemorrhages usually leave patients aphasic and dependent. Thus, treatment 
should be less aggressive than for right-sided lesions. Cerebellar ICH can cause 
respiratory arrest without preceding gradual deterioration of neurologic function 
or alertness, and surgical removal of a portion of the cerebellum often leaves no 
important residual handicap. For these reasons, the threshold for recommending 
surgery for cerebellar hematomas is lower than other lesions of comparable size. 
Cerebellar, lobar  and right putaminal hemorrhages are most accessible to 
surgical drainage. 
Mass Effect and Drainage Pattern 
          Presence of mass effect necessitates surgical drainage. In older patients, 
despite large volume of hematoma, mass effect may be very little because of 
coexisting brain atrophy. The cranial cavity can accommodate excess blood in 
these individuals without much increase in intracranial tension. In some cases of 
ICH, the blood may spontaneously decompress itself into the ventricle. The 
degree of edema also varies with the lesions. Hence the following factors also to 
be taken into consideration while deciding about the surgical drainage. They 
are: 1.presence of hydrocephalus, 2.compression of lateral or third ventricle by 
the hematoma,      3. Presence of midline shift, 4.uncal herniation, 5.effacement 
of ambient cisterns, and 5. Displacement of the fourth ventricle in the presence 
of posterior fossa ICH. Surgical drainage would be indicated more strongly for 
lesions with greater mass effect and no spontaneous decompression. 
Etiology 
 The ICH caused by CAA bleeds after the surgical drainage of the 
hematoma because of the weak vessel wall. The surgery for ICH  due to CAA is 
controversial. Izumihara et.al, in his study of 37 patients with CAA related ICH, 
found out that there is no increased mortality after surgery (113) . However they 
concluded that surgery does not improve the prognosis of the patients 
significantly . 
         If the underlying etiology for ICH is anticoagulant therapy, there will be 
continuous bleeding both per operatively and post operatively. Hence the 
underlying bleeding diathesis should be corrected before undertaking  surgery. 
Although anticoagulant-related hemorrhage patients usually do worse than those 
with other etiologies, some patients have good outcomes after surgical drainage 
despite large size and midline shifts (114).  In case of ICH caused by AV 
malformations , the underlying lesion can be removed at the same time of 
evacuating the hematoma . The threshold for surgical treatment should be most 
favorable for vascular malformations, moderatelyso for accessible lesions 
caused by hypertension, and least favorable for CAA or ICH caused by a 
bleeding diathesis. 
Timing 
 The timing for surgical drainage is not clearly established. Theoretically 
the blood in the hematoma remains in liquid state and can be easily aspirated 
during the initial 3 days. However a study designed to test the hypothesis by 
Morgenstern et al was stopped owing to the increased mortality in the early 
surgical arm because of the increased incidence of rebleeding. In their study, 
rebleeding occurred in 40 % of the patients treated by surgery within 4 hours 
and 12% of patients treated within 12 hours. The mortality rate was very high 
among the patients who rebled.(115).Thus they concluded that early surgery 
promotes rebleeding and thus associated with high mortality. 
 After 7 to 10 days, the hematoma softens and is amenable to aspiration. 
However, patients who survived after one week can have spontaneous 
improvement once the edema subsides. In these patients the advantage of late 
surgery offers questionable benefit. But if the patient has underlying AV 
malformation, surgery for removal of the lesion is advocated. Whether late 
surgery improves the outcome or hastens recovery is not known. Thus the 
guidelines for surgical management on the basis of timing are not clear. 
Clinical Course 
 The most important determinant to be considered in selecting patients for 
surgery is the clinical detoriation of the patient. The emergence of brain stem 
compression signs carries poor prognosis and should be strongly considered for 
emergency surgery if the lesion is surgically accessible.   
 In evaluating the efficacy of surgical vs. medical decompression in 
STICH trial, investigators found out non superiority of early surgery against 
conservative medical management (116). In this single centre randomized 
control study, Morgenstern et al randomized 1033 patients into two groups one 
receiving early surgery and other for conservative treatment. Among the early 
surgery group who underwent surgery within 24 hours, 28% had favorable 
outcome than in the other conservative treatment group which had 24% in terms 
of favorable outcome. 
 Various Meta analysis and other investigators also found no significant 
benefit for early surgery compared to conservative treatment.    
 In various series, depressed level of consciousness is the single most 
important predictor of outcome as measured by Glasgow coma scale.  Large 
hematoma volume (60 mL), midline shift, effacement of the contralateral 
perimesencephalic and ambient cisterns, and dilatation of the contralateral 
temporal horn of the lateral ventricle were the other predictive features. Patients 
who deteriorate during the first 12 hours usually have enlargement of hematoma 
on follow-up CT scans. Those that deteriorate after the first day usually do so 
because of brain edema around the hematoma. 
Treatment strategies to reduce iron related neurotoxicity: 
DEFEROXAMINE. 
 Deferoxamine is isolated from streptomyces pilosus as an iron chelate 
and chemically treated to remove the metal ligand. It had high affinity for the 
ferric iron with low affinity for calcium. It removes iron from hemosiderin and 
ferritin and to a lesser extent from transferrrin. Iron in the hemoglobin or 
cytochromes are not removed. Deferoxamine mesylate (deferral mesylate) is 
poorly absorbed orally and mostly administered parenterally. 
Dosage; 
  IV dose is 10 -15 mg /kg/hr by continuous infusion. 
  IM dose is 50 mg /kg with the maximum of 1 g. 
 Rapid IV boluses are associated with hypotension. It can also occur with 
IM route. Deferoxamine is metabolized by plasma enzymes and readily 
excreted in urine. 
 Deferoxamine causes a number of allergic reactions, including pruritis, 
rash, and anaphylaxis. Other adverse effects include dysuria, diarrhea, fever, leg 
cramps, and tachycardia. Occasional cases of cataract formation have been 
reported. Deferoxamine may cause neurotoxicity in the longrun, both visual and 
auditory changes have been reported (117). 
 Deferiprome is an orally acting iron chelator. Deferasirox is a tridentate 
chelator with a high affinity for iron and low affinity for other metals. It is  
orally active and well absorbed. It binds iron in the circulation and the 
compound is excreted in bile. 
DFX and rat ICH. 
          Masanobu et al in 2009 found out, administration of >10mg/kg of 
deferoxamine to experimentally induced ICH in rats reduced brain edema, 
neurlogical deficits and death.In another study published on 2010, Masanobu 
and coworkers found out beneficial effect of DFX 50mg/kg in 344 rats 
following experimentally induced ICH. They found out the therapeutic window 
of DFX for acute perihematomal brain edema formation is 12 hours. The DFX 
treatment window for long term brain atrophy is 24 hours. The optimal 
therapeutic window is 7 days  (118). 
 
DFX in pigs 
 In an another study using 16 male piglets,Yuxiang gu MD and coworkers 
found deferoxamine at the dose of 50mmg/kg IM reduced the intracerebral 
hematoma induced iron accumulation and neuronal death in treated piglets 
(119). 
DFX and humans. 
 The safety and tolerability of DFX  has been studied in humans. Magdy 
selim and coworkers conducted a phase 1 multicentre dose finding study in 
twenty patients admitted with ICH.The patients were enrolled onto 5 dose tires 
starting with 7 mg/kg/day and ending with 62mg/kg/day as the maximum 
tolerated dose. In that study DFX was discontinued in 2 subjects (10%) because 
of adverse events.6 subjects (30%) experienced serious adverse events none of 
them are related to the drug. Based on that study, they concluded that daily 
infusions of DFX after ICH are feasible, well tolerated and are not associated 
with serious events and mortality. Fifteen percent of the patients had modified 
Rankin score of <2 and 39% had modified Rankin score of 4 to 6 .On day 9, 
0.15% of them died(120) . 
 
 
ERYTHROPOIETIN. 
In a preliminary study, involving healthy volunteers, Damian and coworkers of 
Denmark studied the ferritin lowering effect of EPO. They administered 5000IU 
of EPO and 100 mg/day of ferrous sulphate to healthy volunteers. They found 
hematocrit increased substantially by 12 weeks. By week 6, plasma 
concentrations of ferritin, total iron and transferrin saturation reached a 
nadir.EPOs ability to deplete iron stores and reducing its availability to catalyze 
the free radical formation may offer neuroprotection to the at risk neurons. It 
may be the reason for EPOs potent antioxidant, antiexcitotoxic, antiapoptotic 
and neurogenic properties (121). 
TIRILAZAD MESYLATE: 
           It is a  synthetic, lipid soluble 21 – amino steroid molecule devoid of any 
glucocorticoid activity, that has been tested as a neuroprotectant in acute stroke, 
SAH and traumatic brain injury. It belongs  to the class of Lazaroids. The main 
mechanism of action is by inhibition of iron dependent lipid peroxidation by the 
following mechanism, 
1.free radical scavenging. 
2.reducing the formation of hydroxyl radical. 
3.decreasing membrane phospholipid fluidity. 
4.maintaining endogenous antioxidant levels ,especially Vitamin E and C. 
  In a systemic review published by TRILIZAD INTERNATIONAL 
STEERING COMMITTEE REVIEW  by Prof.Bath et.al, it has been concluded 
that Trilizad mesylate increased mortality and morbidity in about  one fifth of 
the patient. This conclusion is based on the review of the 4 clinical trials (122). 
Other drugs that has putative neuroprotection , but associated with poor 
outcome in clinical trials include, 
1.Selfotel – a glutamate receptor antagonist, 
2.Enlimomab- an anti intercellular adhesion molecule antiboby, 
3.Diaspirin linked hemoglobin, 
4.Aptigenel –NMDA receptor blocker, 
5..calcium channel blockers such as nimodipine, flunarazine etc, 
6.Eliprodil- NMDA receptor antagonist, 
7.Lubeluzole – a molecule with nitric oxide modulating activity, 
8.GV 150526 –glycine receptor antagonist. 
Calculating the volume of ICH : 
 The volume of the hematoma can be accurately measured by on the 
bedside in a plain CT brain by using the formula of ellipsoid. In the parenchyma 
, the hematoma assumes the shape of a ellipsoid. The simplified formula of the 
ellipsoid is ABC/2. 
VOLUME OF ICH IN ml =  A X B X C /2, 
 Whereas, 
 A = the largest cross-sectional diameter . 
B= the largest diameter perpendicular  to A on the same slice . 
C = the approximate number of 10 mm slices on which the ICH is seen  
/2 = added to approximate the volume of an ellipsoid . 
 The slice of the CT in which the hematoma is seen largest should be 
selected as an index slice. A & B are measured in centimeters to the nearest 0.5 
cm. in other slices if the diameter is more than 75 % of the index slice, it is 
counted as one slice. If the diameter is between 25 to 75 %, the silce count is  
0.5. the slices with diameter less than 25 % should be ignored. Similarly , if 
thickness of the slice is 0.5 mm , the total number slices should be divided by 2. 
Kothari et .al . demonstrated that the volume of ICH can be accurately measured 
by this method in less than one minute (123). 
  Gabel et al compared the ABC/2 formula with computer volumetric 
analysis and concluded that they are comparable in accuracy in measuring the 
volume of hematoma if the borders of the hematoma are comparably rounder 
(124). 
 Hattner et .al . suggested the denominator of 3 instead of 2 in 
anticoagulation related hemorrhage , because most of the hemorrhage assumes 
multilobulated appearance (125). 
  
 
 
Modified Rankin scale: 
 The  Rankin scale was  first introduced  by  Rankin in 1957 (126)  to 
assess the disablity and dependency after a atroke. It was later modified by  
Lindley et al in 1994  (127). 
 The scale 0 is the state of perfect health  and scale 6 is death. 
0 - No symptoms. 
1 - No significant disability. Able to carry out all usual activities, despite some 
symptoms. 
2 - Slight disability. Able to look after own affairs without assistance, but 
unable to carry out all previous activities. 
3 - Moderate disability. Requires some help, but able to walk unassisted. 
4 - Moderately severe disability. Unable to attend to own bodily needs without 
assistance, and unable to walk unassisted. 
5 - Severe disability. Requires constant nursing care and attention, bedridden, 
incontinent. 
6 - Dead. 
 
 
 
 
 
 
           MATERIALS AND METHODS 
Venue 
 This study was conducted in the Institute of Internal Medicine at Rajiv 
Gandhi  Government  General Hospital , Madras Medical College, Chennai 
from May 2012 to November 2012. 
Study Design 
 This was a hospital based observational  study. 
Sample Profile  
 A group of 50 subjects participated in this study.    
Inclusion criteria for study patients 
  First episode of Primary supratentorial hemorrhage diagnosed clinically 
and by computed tomography of brain. 
Exclusion criteria for study patients . 
1. Ischemic  stroke, 
2. Anemia , 
3. Severe alcohol consumption, 
4. Chronic liver disease. 
5. Chronic kidney disease. 
6. Hematological cancer. 
7.  Secondary intracerebral hemorrhage. 
STUDY PROTOCOL 
1. Clinical Evaluation 
 A standard proforma designed for the study was used.  On admission, a 
complete history was obtained from every patient including symptoms of 
headache, vomiting, loss of consciousness, seizures and focal neurological 
deficit. History of hypertension , diabetes mellitus , drug history including use 
of anticoagulation  were noted.  Clinical evaluation was carried out  noting vital 
parameters, clinical signs of focal neurological deficit and signs of increased 
intracranial tension.  Glasgow coma scale was  used to assess  the stroke 
severity. Other systems were also examined to find significant comorbidities.  
All patients were treated according to the established guidelines  at the time of 
study. 
2.Radialogical evaluation: 
 All the patients were subjected to non enhanced computed tomography 
scan of the brain. Primary intracerebral hemorrhage located in the supratentorial  
region were selected. The location of the hematoma, presence of midline shift  
and  intraventricular extension of bleed were assessed. The size of the 
hematoma was calculated using the  Ellipsoid Formula.  
3. Assay of Biochemical Parameters 
 After getting informed consent from all the participants,  2ml of venous 
blood   was collected by sterile venepuncture  within 72 hours of symptom 
onset. Serum ferritin levels were estimated by ELISA method. Simultaneously 
renal function , liver function and complete blood count and peripheral smear 
study were carried out. 
 4. Evaluation of prognosis 
  All the study patients were assessed using the modified Rankin scale at 
the end of first week and at the end of one month follow up. The score of  0-2 
was considered good prognosis. The score of 3-5 was considered bad prognosis 
and the score 6 was given to the event of death. 
5.Statistical Analysis: 
  The variables were analysed using SPSS software version 15. Students ‗t‘ 
test and chi square tests were employed to find out significance of difference 
between means in study patients. Variables are analysed using one way 
ANOVA between different prognostic groups.Spearman‘s correlation analysis 
was used to find correlation between serum ferritin and GCS and volume of 
hematoma. 
7.Estimation of serum ferritin levels using quantitative ELISA ferritin test 
system: 
Principle 
This is the classic sandwich ELISA assay using ACCUBIND SERUM 
FERRITIN KIT OF MONOBIND INC.U.S.A.  It is 
IMMUNOENZYMOMETRIC SEQUENTIAL ASSAY TYPE 4. 
The essential reagents required for an immunoenzymometric assay 
include high affinity and specificity antibodies ( enzyme and immobilized ), 
with different and distinct epitope recognition, in excess , and native antigen. In 
this procedure , the immobilization takes place during assay at the surface of a 
microplate well through the interaction of streptavidin coated on the well  and 
exogenously added biotinylated monoclonal anti- ferritin antibody. 
Upon mixing  monoclonal  biotinylated antibody, and a serum containing 
the native antigen, reaction results between the native antigen and the antibody, 
forming an antibody – antigen complex. Simultaneously the biotin attached to 
the antibody binds to the streptavidin coated on the microwell resulting in 
immobilization of the complex. The reaction is illustrated by the following 
equation; 
  Ag(ferritin) +
btn 
Ab(m) ↔Ag(ferritin) – btnAb (m).----1 
          
btn 
Ab(m) = biotinylated monoclonal antibody (excess quantity). 
  Ag(ferritin) = native antigen (variable quantity). 
 Ag(ferritin) – btnAb (m). = antigen antibody complex.   
     (variable quantity). 
Ag(ferritin) – btnAb (m).+ streptovidincw ===>immobilized complex (ic)--
--2 
  streptovidincw = streptovidin  immobilized on well. 
  Immobilized complex (ic) =Ag-Ab bound to the well. 
    After a suitable incubation period , the antibody-antigen bound fraction 
is separated from unbound antigen by decantation or aspiration. Another 
antibody (directed against different epitope) labeled with an enzyme is added .  
Another interaction occurs to form an enzyme labeled antibody-antigen-
biotinylated-antiody complex on the surface of the wells. Excess enzyme is 
washed off  via a wash step. A suitable substrate is added to produce color, 
measurable with the use of a microplate spectrophotometer. The enzyme 
activity on the well is directly proportional to the native antigen concentration. 
By utilizing several different serum references of  known antigen concentration 
, a dose response curve can be generated from which the antigen concentration 
of an unknown can be ascertained. 
(IC) + 
enz
Ab(ferritin) ↔enz Ab(ferritin)-IC  -----3. 
 
enz
Ab(ferritin) = enzyme labeled antibody (excess quantity). 
 enz 
Ab(ferritin)-IC  = antigen antibody complex. 
 
 
 
 
 
 
 
 
 
   OBSERVATION AND RESULTS 
Total number of subjects;50 
Age wise distribution  
AGE IN YEARS Frequency Percentage 
 
< 40 6 12% 
41 – 50 10 20 % 
51 – 60  18 36% 
61-70 12 24% 
>  70 4 8% 
Table 1. Age distribution of study population. 
 
Chart 1.Age distribution of study population. 
 Majority of the patients belong to the age between 51 to 70 years.the 
minimum age was 30 years and maximum age was 80 years. 
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 Sex Frequency percentage 
Male 39 78 
female 11 22 
Table 2. sex distribution of study population. 
 
chart 2. Sex distribution of study population. 
 
PROGNOSTIC GROUPS. 
 
Chart 2 a. Different prognostic groups. 
Total study patients                                      = 50. 
Patients with MRS  < 2 (Good prognosis)   = 8. 
Patients with MRS 3-5 ( Bad prognosis)   =  27. 
Patients with MRS  6 ( Death )                     =15. 
 
 
 
MALE, 78%
n=39
FEMALE, 22%
n=11
Good 
prognosis, 8
Poor 
prognosis, 27
Death, 15
Location of hemorrhage 
site  Frequency Percentage 
Lobar 11 22 
Gangliocapsular 32 64 
Thalamus 7 14 
Table 3. location of hematoma in study population. 
 
 
Chart 3. Location of  hematoma in study population. 
 
 The most common location of hematoma in the study population is 
gangliocapsular region and is most consistent with the site of hypertensive 
hemorrhage ( 64 %).The thalamus is least affected in the study (14 %).  
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Volume of ICH 
Volume (ml) Frequency Percentage 
< 30 9 18 
31 – 60 20  40 
61 – 90 15 30 
91 – 120 4 8 
>120 2 4 
Table 4. volume of hematoma. 
 
 
Chart 4.volume of Hematoma. 
 About 40 % of the study population has hematoma volume between 31 
to 60 ml. The mean volume of hematoma is 59.58 ml. 
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Risk factors 
 Risk factor Frequency Percentage 
Hypertension 49 98 
Diabetes 9 18 
Smoking 33 66 
Alcoholism 24 48 
Table 5. risk factors among the study population.  
 
Chart 5. Risk factors among study population. 
  
 Hypertension is present in 98 % of the patients and is the most common 
etiology in ICH. Diabetes is present in  18 % of the study population. 43 male 
patients were smokers and 24 of them are alcoholic. 
 
 
 
 
 
Hypertension
42%
Diabetes
8%
Smoking
29%
Alcoholism
21%
Symptomatology 
Symptoms Frequency Percentage 
Headache 25 50 
Vomiting 15 30 
LOC 10 20 
Seizures 5 10 
FND 50 100 
Table 6. frequency of symptoms among the study population. 
 
 
 
Chart 6. Frequency of symptoms among study population. 
 
 Headache is the second most common symptom after focal neurological 
deficit with frequency of 50%. The incidence is higher than that of quoted in 
other studies. 
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MORTALITY DATA : 
Total number of subjects =50  
Total number of deaths=15 
Total number of survivors= 35  
 Age wise distribution  
AGE IN YEARS Frequency Percentage 
 
< 40 2 13.33 
41 – 50 1 6.66 
51 – 60  7 46.66 
61-70 3 20.00 
>  70 2 13.33 
 
Table 7. Age distribution of mortality. 
 
Chart 7. Age distribution of mortality.The overall mortality is 30 %.The 
maximum number of mortality happened among the age group of 51 -70 years  
accounting for 66.6%. 
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 Sex Frequency Percentage 
Male 12 80 
female 3 20 
Table 8. sex distribution of mortality. 
 
 
Chart 8. Sex distribution of mortality. 
 The mortality was high among males  ( 34.28 %) than that of females(20 
%).  
 
 
 
 
MALE,  80%
n=12
FEMALE, 20%
n=3
Volume of ICH 
Volume (ml) Frequency Percentage 
< 30 0 0 
31 – 60 4 26.66 
61 – 90 8 53.33 
91 – 120 2 13.33 
>120 1 6.66 
Table 9. volume of ICH among the dead. 
 
Chart 9. volume of ICH among the dead. 
 
 frequency Percentage 
Midline shift 1 6.66 
IVH 8 53.33 
Table 9 a. other CT characteristics. 
  The mean volume of the hematoma is 78.66 ml ( SD 23.295). The 
presence of intraventricular extension  is noted in 53.33% of patients and 
significant midline shift in 6.6%. 
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Risk factors 
 Risk factor Frequency Percentage 
Hypertension 15 100 
Diabetes 5 33.33 
Table 10. Distribution of risk factor among the dead. 
 
 
Chart 10. Distribution of risk factor among the dead. 
 
  
 
 Hypertension is present in all the patients among the dead. Diabetes is 
present in 33.33 5 of the patients. 
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HYPERTENSION
DIABETES
Location of hemorrhage 
site  Frequency Percentage 
Lobar 4 26.66 
Gangliocapsular 9 60.00 
Thalamus 2 13.33 
Table 11. location of hematoma among dead. 
 
 
Chart 11. location of hematoma among dead. 
  
 
 The ganglio capsular region is the common site affected by ICH 
 (60 %).  
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Table 12. serum ferritin values in the mortality group. 
 
 Chart 12.serum ferritin values in the mortality group. 
  
 The serum ferritin is significantly elevated in this group with MRS = 6. 
The mean value is 363.4 ng/ml (SD 46.14). This is statistically significant with P 
<0.05. 
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Sr.ferritin (ng/ml) Frequency Percentage 
< 200 O O 
200 – 300 2 13.33 
300 – 400 9 60.00 
>400 4 26.66 
 GOOD PROGNOSTIC GROUP MRS 0-2 
Age wise distribution  
AGE IN YEARS Frequency Percentage 
 
< 40 4 50 
41 – 50 1 12.50 
51 – 60  2 25.00 
61-70 1 12.50 
>  70 0 0 
 
Table 13. Age distribution among good prognostic group. 
 
 
Chart 13. Age distribution among good prognostic group. 
 Persons less than 40 years of age has good prognosis compared to other 
age groups. There is no persons aged above 70 has good prognosis. 
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Risk factors 
 Risk factor Frequency Percentage 
Hypertension 8 100 
Diabetes 0 0 
Table 14. risk factor among good prognosis group. 
 
 
 
Chart 14. risk factor among good prognosis group. 
 
  The patients with no diabetes had good prognosis. 
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Location of hemorrhage 
site  Frequency Percentage 
Lobar 0 0 
Gangliocapsular 1 12.50 
Thalamus 7 87.50 
Table 15. Location of hematoma among good prognostic group. 
 
 
 
chart 15. Location of hematoma among good prognostic group. 
   
 About 87 % of the patients in the good prognostic group had their 
hematoma located in thalamus. 
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Volume (ml) Frequency Percentage 
< 30 4 50.oo 
31 – 60 2 25.00 
61 – 90 2 25.00 
91 – 120 0 0 
>120 0 0 
Table 16. volume of ICH in good prognostic group. 
 
Chart 16. volume of ICH in good prognostic group. 
- Frequency Percentage 
Midline shift 0 0 
IVH 0 0 
Table 16 a . Other CT findings. 
 Most of the patient  had their hematoma volume less than 30 ml ( 50 %). 
The mean volume of hematoma was 24.12 ml with SD 8.39. The difference is 
statistically significant ( p < 0.05). There is no evidence of IVH and midline shift. 
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Serum ferritin values 
Sr.ferritin (ng/ml) Frequency percentage 
< 200 8 100 
200 – 300 0 0 
300 – 400 0 0 
>400 0 0 
Table 17. serum ferritin values in good prognostic group. 
 
 
Chart 17. serum ferritin values in good prognostic group. 
 
 All 8 patients in the good prognostic group hasd their ferritin value less 
than 200 ng/ ml .The mean  serum ferritin value was 111.0 ng/ml (SD 32.08). 
This is statistically significant with P < 0.05.  
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BAD PROGNOSTIC GROUP MRS 3-5 : 
Age wise distribution  
AGE IN YEARS Frequency Percentage 
 
< 40 1 3.70 
41 – 50 7 25.92 
51 – 60  9 33.33 
61-70 8 29.62 
>  70 2 7.40 
 
Table 18. Age distribution of patients in  poor prognostic group. 
 
 
Chart. 18. Age distribution of patients in  poor prognostic group. 
 Most of the patients with poor prognosis were within the age group of 
51 to 70 years ( 62.95 %). 
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Risk factors 
 Risk factor Frequency Percentage 
Hypertension 27 100 
Diabetes 5 18.51 
Table 19. Risk factors among poor prognostic group.  
 
Chart. 19. Risk factors among poor prognostic group. 
 
 All patients in this group had hypertension and among 9 diabetic 
patients ,5 had poor prognosis (55.55 %). 
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Location of hemorrhage 
site  Frequency Percentage 
Lobar 4 14.81 
Gangliocapsular 19 70.37 
Thalamus 4 14.81 
Table 20. location of hematoma among poor prognostic group. 
 
 
 Chart. 20. location of hematoma among poor prognostic group. 
  
 
  The most common location was gangliocapsular region. 
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Volume (ml) Frequency Percentage 
< 30 3 11.11 
31 – 60 14 51.85 
61 – 90 7 25.92 
91 – 120 2 7.40 
>120 1 3.70 
Table 21. volume of hematoma in poor prognostic group. 
 
 Chart.21. volume of hematoma in poor prognostic group. 
 The mean volume of hematoma in this group was  59.48 ml  ( SD 25. 97) 
, and it is statistically significant ( P < 0.05 ) . 
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Serum ferritin values 
Sr.ferritin (ng/ml) Frequency Percentage 
< 200 7 25.92 
200 – 300 15 55.55 
300 – 400 1 3.70 
>400 4 14.81 
Table 22. serum  ferritin values in poor prognostic group. 
 
 Chart.22. serum  ferritin values in poor prognostic group. 
 Fifty five percentage of patients had their serum ferritin values in the 
range of 200 – 300 ng/ml. Four patients had their serum ferritn value more 
than  400 ng / ml. The mean serum ferritin value was 265.11 ng/ml (SD 84.04).  
This difference is statistically significant ( P < 0.05).   
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 Chart 23.comparison of volume and serum ferritin levels in various groups.  
In general, 
 Mean volume of ICH==78.66ml. 
 Mean value of ferritin==363.40 ng/ml 
In good prognostic group, 
 Mean volume of ICH = 24.12 ml 
 Mean value of sr ferritin = 111 ng/ml. 
In bad prognostic group,  
 Mean volume of ICH = 59.48 ml  
 Mean ferritin value = 265.11 ng/ml. 
In mortality group, 
 Mean volume of ICH = 78.66 ml. 
 Mean  ferritin  value= 363.40 ng/ml. 
     Group frequency Mean  S.Deviation Median  
  Good prognosis 8 12.125 0.9910    12.000 
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Table 24. comparison of GCS among different prognostic groups. 
 
Chart. 24. Comparison of GCS among different prognostic groups  
( P < 0.001)  CI 95%.  
On comparing, the difference in admitting GCS between different prognostic 
groups is statistically significant with P < 0.001 and confidence interval of 95%. 
 
 
 
          Group 
 
Points 
 
Mean 
 
S.Deviation 
 
Median 
Good 
prognosis  
(Column A) 
8 24.125 8.391  24.000 
 Poor 
prognosis 
 ( Column B) 
27 59.481 25.972 56.000 
 Mortality 
(Column C) 
15 78.667 23.295 80.000 
 Table 25.  Comparison of volume  of hematoma in different prognostic 
groups. 
 
Chart 25. Comparison of volume of hematoma in different prognostic groups. 
( P < 0.05 ). CI 95%. 
 On comparing, the hematoma volume between different prognostic 
groups  is statistically significant with P< 0.05 and CI 95%. 
     Group 
 
Points 
 
Mean 
 
S.Deviation 
 
Median  
      Column A 8 111.00 32.018 121.00 
      Column B 27 265.11 84.045 260.00 
      Column C 15 363.40 46.176 372.00 
Table 26. comparison of serum ferritin values among different prognostic 
groups. 
 
 
Chart. 26. comparison of serum ferritin values among different prognostic 
groups ( P<.05, CI 95%) 
 
 On comparing , there is statistically significant difference of serum ferritin 
levels between different prognostic groups. 
 
 
  
 
 
 
 
                       There is no correlation between volume ,GCS and serum ferritin in 
different prognostic groups. 
       
mortality
serum ferritin
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Chart 27.corelation between 
volume ,GCS and ferritin in good 
prognostic group. 
The two-tailed P value is 0.4646, 
considered not significant. Chart 29.corelation between 
volume ,GCSand ferritin in good 
prognostic grou. 
The two-tailed P value is 0.4646, 
considered not significant. 
Chart 28.corelation between 
volume ,GCS and ferritin in poor 
prognostic group.  
The two-tailed P value is 0.5597, 
considered not significant 
Chart 29.corelation between 
volume ,GCS and ferritin in poor 
prognostic group.  
The two-tailed P value is 0.9551, 
considered not significant 
 
                                      DISCUSSION 
  This study was conducted on 50 patients with acute intracerebral  
hemorrhage  to find out the serum ferritin levels and correlation between different  
prognostic groups. 
 In the previous studies by William Whitely et al (128),the other variables 
that are associated with poor outcome include , body temperature, blood glucose, 
C-RP, WBC , serum cortisol , elevated plasma and CSF levels of glutamate, 
glycine and IL-6. 
 It is likely that the inflammatory response is triggered by stroke  process  
and mediated by IL-1 ( fever) and IL-6 / TNF with rise in acute phase reactants 
such as C-RP etc  that may enhance neurotoxicity. However the initial rise in 
serum ferritin levels at the onset of stroke is not associated with inflammatory 
response and correlate with the body iron stores. In the study by Natalia Perez et 
al , it has been proved that the serum ferritin levels are not correlated with other 
markers of inflammatory response (49). It is again confirmed by Armengolu et 
al.(50). 
 Antonio Davlos et al has also proved association between increased body 
iron stores as measured by serum ferritin and clinical detoriation of acute cerebral 
infarction. 
 The beneficial effect of iron chelation by deferoxamine has been proved in 
experimental animals by independent investigator ; Masanobu et.al. in rats ( 118) 
and Yuxiang gu in piglets ( 119). No adverse effects was found out in humans 
with desferoxamine infusion by Magdy selim (120). So if the role of Iron in ICH 
is proved by  many studies with large sample size , the role of iron chelation can 
be studied in future. 
 In this current study of 50 patients with primary supratentorial hemorrhage  
admitted in our hospital , the incidence of ICH is high among the age group of 51 
– 70 years. The mean age of onset of ICH  reported by Natalia Perez was 66 
years. 
 Males are more commonly affected 4 times higher than females ( 4:1). 
Hypertension is the most commonly associated risk factor  ( 98%) in this study 
population. It is similar to the other study series and is the most common cause of 
ICH worldwide as reported by Caplan and Kase ( 69). Diabetes mellitus is 
present in 18 % of the study population.  
 The most common location of hypertensive ICH is lateral gangliocapsular 
region. In a clinico pathological series by Cole and Yates, it has been found that 
the microaneurysms caused by hypertension were commonly located in this 
region ( 70). In our study, the most common location of ICH is gangliocapsular 
region followed by lobar and thalamus. Older patients are having little higher 
incidence of lobar hemorrhage located in temperoparietal region. The cerebral 
amyloid angiopathy as a cause of lobar hemorrhage in older age group cannot be 
ruled out in the absence of follow up and histopathalogical correlation.   
  Headache is the second most common symptom after focal neurological 
deficit. It is present in 50% of the study population. It is in contrast to other series 
in which headache is present in only in 40 %. 
 The overall mortality is 30 % in this study population. This is also higher 
than the reported mortality rate of 10 – 20 % among developed countries. In part 
it can be explained by lack of long term care facilities in most part of India and 
associated complications of immobilization. The average mortality rate reported 
by Das et.al is 18 -41 % in India ( 9, 10).  
 The high mortality occurs in age group of 51 – 70 years in this study 
population (66.66 %). Ten out of thirty patients in this age group died due to ICH. 
 The serum ferritin levels are significantly elevated among the bad 
prognostic group with Modified Rankin Score of more than 2. The mean serum 
ferritin value is 111 ng/ml ( SD 32.018). The mean ferritin values are 265.11 
ng/ml ( SD 84.04) and 363.40 ng /ml in patients with MRS 3 to 5 and 6 
respectively. The difference is statistically significant ( p < 0.05).  Hence the 
serum ferritin level at the baseline  can be used as a prognostic marker in ICH. 
This is similar to the results obtained by Natalie et.al in his study. The mean 
ferritin value in that study was 270.6 ng/ml in bad prognostic group ( 49). 
 Among other prognostic factors, GCS and volume of ICH are positively 
correlated with the prognosis. The mean GCS in study population with MRS < 2 , 
3-5 and 6 are 12 (SD 0.09), 8 (SD 1.6) and 5.5 ( SD 1.7) respectively.  The 
difference is statistically significant with P< 0.05. The correlation between GCS 
has been proved by Kase and Crowell  (60).  
 The volume of ICH is another independent predictor of prognosis (108). In 
our current study the mean volume of ICH are 24 ml ( SD 8.3) , 59.48 ml ( SD 
25.97) and 78.66 ml ( SD 23.29 ) among the patients with MRS < 2 , 3-5 and 6 
respectively. This observation is statistically significant ( P < 0.05). 
 Manu Mehriditta found no significant correlation between the serum 
ferritin levels and the volume of ICH  ( 46). In our study ,the serum ferritin values 
have no significant correlation either with admitting GCS and volume of 
hematoma in all prognostic groups ( tailed P value >0.05). Hence the serum 
ferritin values are independent of other markers of prognosis.   
 
 
 
 
 
    CONCLUSION   
 In our study of 50 patients with primary supratentorial intracerebral 
hemorrhage , 
1. The baseline serum ferritin can be used as an independent prognostic 
marker. 
2. The serum ferritin levels are not influenced by the volume of ICH and 
admitting GCS. 
3. The increased body iron stores as measured by ferritin is associated with 
clinical detoriation. 
4. The hypertension is the most common risk factor associated with ICH. 
5. The most common site of bleed is gangliocapsular region. 
6. The absence of diabetes, younger age and absence of IVH and midline shift 
are associated with good prognosis. 
7. The presence of low GCS is associated with poor prognosis. 
8. The higher the volume of hematoma, poorer the prognosis. 
9. The initial volume of hematoma as measured by ABC/2 is accurate in 
predicting prognosis. 
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   ABBREVATIONS 
 
AVM      Arteriovenous malformation 
CRP    Complement reactive protein.  
CSF    Cerebro spinal fluid. 
CAA    Cerebral amyloid angiopathy. 
CTA    CT-angiography. 
DALY    Disablity adjusted life years. 
DFX    Deferoxamine. 
EPO    Erythropoietin 
GCS    Glasgow coma scale. 
H-CHAIN    Heavy chain. 
ICH    Intracerebral hemorrhage. 
IVH    Intraventricular hemorrhage. 
LSD    Lysergic acid diethyamide. 
LOC    Loss of consciousness. 
L-CHAIN   Light chain. 
LDL    Low density lipoprotein. 
Mcg     Microgram. 
NPBI    Non protein bound iron. 
PPA    Phenyl propanolamine. 
PCP    Phencyclidine. 
SHIP     Study of health in Pomerania. 
Sr    Serum 
STICH    Surgical treatment for intracarebral hemorrhage . 
 
 
PROFORMA. 
EVALUATION OF SERUM FERRRITN LEVELS AS A PROGNOSTIC MARKER 
IN ACUTE HEMORHAGIC STROKE. 
 
 NAME :      AGE:     
 SEX:  
 ADDRESS:      I.P.NO:   
   
 
 PAST HISTORY: 
o CVA.  CHD.  CKD.  SHT.  DM. 
 CLD.  
o Hemophilia.   Leukemia.  Rheumatoid arthritis. 
 DRUG HISTORY:  
o Antiplatlets.   Anticoagulants. 
o Others. 
 PERSONAL HISTORY:  
o Smoking.    Alcohol. 
o Narcotics . 
 
  CLINCAL FEATURES: 
o Symptoms:      Headache. 
 Vomiting.  
  
 Convulsions. 
 Diplopia. 
 Blurring of vision. 
 Trauma.  
o Signs: 
 Vitals 
o PR:  BP:  RR:  GCS:   
o TEMP 
 cranial nerves.  
 Pupils 
 Motor weakness.  
 Sensory abnormalities.  
 Bladder and bowel. 
 Involuntary mvt.  
 Papiledema 
  
 OTHER SYSTEMS : 
 CVS;     RS;   ABD; 
     
 SK.DEFORMITIES;    
 INVESTIGATIONS: 
o CBC:    RFT:   eGFR: LFT: 
 
 
o Peripheral smear: 
 
o USG abodomen: 
 
 
o CT BRAIN: 
 Location.     Volume.  
 Midline shift.   IVH.  
 
o Serum ferritin.        
  
 GCS: 
 
 Modified Rankin score: 
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1. Boss 64/M 61513 - - + - - + - 68 170 
100 
12 N N LHP N 12 R.GC 60 - + 420 5 5 
2. Indhrani 65/F 63007 + - + + - + - 96 180 
96 
14 N N RHP N 4 LTP 86 + + 264 6 - 
3. Nallusamy 66/M 65463 - - + - - + + 66 200 
100 
 
15 N N LHP N 3 RGC 90 - - 412 6 - 
4. Kannan 72/M 65484 - - + - - + - 74 170 
100 
14 N N LHP N 7 RGC 40 - - 296 5 4 
5. Mariyadass 30/M 65998 + + + - + + - 69 180 
108 
13 N N LHP N 10 RGC 36 - - 213 3 3 
6. Kamatchi 33/F 67034 + + + - - + - 84 160 
96 
16 N N RHP N 11 LGC 24 - - 142 2 2 
7. Ravindran 50/M 68008 - - + - - + - 72 156 
100 
12 N N RHP N 9 LGC 74 - - 236 5 4  
8. Babu 65/M 70404 - + - - - + + 80 172 
112 
13 N N LHP N 7 R.THAL 66 - - 420 5 5  
9. Samuvel 49/M 70497 - - + - - + - 63 148 
94 
14 N N RHP N 6 LGC 40 - - 180 4 3  
10. Chakkubai 46/M 71228 + - + + - + + 99 154 
92 
16 N N LHP N 7 RGC 78 - + 262 5 4  
11. Krishnan 36/M 71268 + - + - + + - 78 146 
80 
13 N N LHP N 13 RGC 12 - - 130 2 2  
12. Karunakaran 55/M 73160 - - + - - + - 66 156 
100 
12 N N LHP N 11 RGC 46 - - 189 3 3  
13. Thangaraj 70/M 74834 - + + - + + + 60 164 
110 
13 N N RHP N 5 LTP 80 - - 403 6 -  
14. Anandhan 80/M 75151 - - + - - + - 83 172 
98 
14 N N RHP N 3 LGC 86 - - 292 6 -  
15. Rajan 64/M 76051 - - + - - + - 70 148 
90 
12 N N LHP N 12 R THAL 34 - - 138 2 2  
16. Pandaram 65/M 77514 - - + + - + - 84 178 
100 
14 N N LHP N 8 RGC 94 - - 400 5 5  
17. Jacob 57/M 80783 + - + - - + - 60 152 
94 
12 N N RHP N 9 L THAL 20 - - 231 4 4  
18. Balan 58/M 80825 + + + - - + - 76 182 
100 
16 N N RHP N 7 LGC 44 - + 372 6 -  
19. Rajeswari 85/F 81245 - - + + - + + 66 140 
90 
13 N N RHP N 10 LTP 26 - - 172 4 4  
20. Samundeeswari 55/F 83787 + + + - + + - 56 166 
98 
15 N N RHP N 5 LGC 58 - + 312 5 6  
21. Gowridevi 43/F 83866 + + + - - + - 77 158 
98 
12 N N RHP N 10 LGC 90 - - 282 5 4  
22. Indhrani 70/F 86078 - - + - - + - 98 146 
100 
 
16 N N RHP N 11 L THAL 48 - - 166 3 3  
23. Raj 54/M 87555 + - + - - + - 65 170 
98 
15 N N LHP N 14 RGC 23 - - 116 2 1  
24. Jonadoss 40/M 87794 + + + + - + - 78 196 
110 
12 N N RHP N 5 LGC 110 - - 398 5 6  
25. Iyyappan 55/M 88068 - - + - - + + 84 164 
96 
12 N N LHP N 5 RTP 124 - - 366 6 -  
26. Raghunandhdan 43/M 89638 + + + - - + - 56 148 
74 
15 N N LHP N 9 RGC 86 - - 269 4 4  
27. Kathirvel 60/M 90717 - - + - - + - 72 150 
90 
12 N N RHP N 8 L THAL 76 - + 364 6 -  
28. Janaki 70/F 90724 - - + - - + + 66 148 
78 
11 N N RHP N 10 LGC 40 - - 296 5 5  
29. Prabakar rao 40/M 92628 - - + - - + - 72 176 
96 
13 N N LHP N 4 R THAL 80 - + 382 5 6  
30. Ravi 35/F 94256 + - + + - - - 68 138 
98 
12 N N LHP N 12 LGC 14 - - 126 2 1  
31. Patchiappan 70/M 96471 - - + - - + - 87 156 
94 
14 N N LHP N 8 RGC 44 - - 156 3 3  
32. Krishnan 80/M 96788 - - + - - + + 68 180 
94 
11 N N RHP N 8 LTP 36 - + 400 5 6  
33. Gubendran 65/M 97135 - - + - - + - 56 176 
76 
12 N 1N RHP N 9 LGC 58 - - 340 5 4  
34. Murali 56/M 97469 + - + - - + - 67 180 
108 
16 N N LHP N 12 RGC 36 - - 56 2 1  
35. Kumar 52/M 97583 - - + - - + + 78 156 
98 
14 N N RHP N 9 LTP 126 - - 196 5 4  
36. Kanim 55/M 98152 + - + - - + - 89 148 
112 
13 N N LHP N 8 RTP 86 - + 236 4 4  
37. Thangaraj 60/M 98207 - - + + - + - 66 156 
78 
12 N N LHP N 7 RGC 74 - - 358 5 6  
38. Arumugam 45/M 99548 + - + + - + - 79 180 
98 
12 N N RHP N 8 LGC 96 - + 196 5 4  
39. Dhandapani 52/M 99603 + - + - - + - 64 146 
76 
15 N N RHP N 7 LGC 43 - - 224 4 4  
40. Ramakrishnan 53/M 99739 + + + - - + - 56 180 
110 
12 N N RHP N 6 LGC 76 - - 480 5 5  
41. Bhgavan 45/M 100070 - - + - - + - 66 178 
90 
13 N N LHP N 12 RGC 24 - - 68 2 1  
42. Rajamanickam 56/M 100114 + + + + - + - 70 176 
100 
12 N N RHP N 6 LGC 56 - + 412 5 6  
43. Usman 68/M 100311 - - + - - + - 65 178 
98 
13 N N RHP N 5 LGC 84 - - 320 6 -  
44. Ibrahimbai 45/M 101684 + + + - - + - 76 168 
96 
12 N N RHP N 8 LGC 60 - - 281 4 4  
45. Mohan rao 55/M 102462 + - + - + + - 66 148 11 N N LHP N 8 R PAR 15 - - 270 5 4  
96 
46. Nirmala 65/F 102831 + + + + - + - 60 178 
90 
14 N N RHP N 7 L THAL 56 - - 260 4 4  
47. Lakshmi 56/F 102914 - - + - - + - 61 148 
94 
12 N N LHP N 8 RGC 96 - + 396 6 -  
48. Ramayee 45/F 103599 + + + - - + - 72 154 
94 
11 N N RHP N 6 LGC 46 - - 275 5 5  
49. Suresh 36/M 103602 + + + - - + - 54 178 
100 
10 N N LHP N 11 RGC 26 - - 112 2 2  
50. muthulingam 57/M 103612 + - - - - + - 74 180 
98 
12 N N LHP N 10 RGC 56 - - 212 3 3  
 
    KEY TO MASTER CHART. 
 B.P    Blood pressure. 
C.V.S    Cardiovascular system. 
C.N.S    Central nervous system. 
F    Female. 
G.C.S    Glassgow coma scale. 
I.V.H    Intraventricular hemorrhage.  
L.O.C    Loss of consciousness. 
L.G.C    Left gangliocapsular region.  
L.T.P    Left  temperoparietal region. 
L.THAL   Left  thalamus. 
M    Male. 
M.R.S    Modified Rankin scale. 
R.S    Respiratory system. 
R.R    Respiratory rate. 
R.T.P    Right  tempero parietal region. 
R.G.C    Right ganglio capsular region. 
R.THAL   Right thalamus. 
+    Present. 
-    Absent. 
 
  
 
 
  
